[
  {
    "objectID": "data_metabolic_syndrome.html",
    "href": "data_metabolic_syndrome.html",
    "title": "Data Description/Processing - Metabolic Syndrome In Rats",
    "section": "",
    "text": "The study is a comparative analysis of two different models of metabolic syndrome, high fat and high fat+high fructose, in rats using a metabolomic approach.\nThe main questions it attempts to answer are: Which of the two models is more suitable for drawing conclusions about the human pathology of metabolic syndrome? Is there a differentiation of the metabolomic profile between the two dietary models? Is either of the profiles closer to the average metabolic profile of an individual with metabolic syndrome? Does either of the two models reveal early biomarkers? If so, do any of them match known human markers? The experimental models were designed for a duration of 8 weeks, but the study was extended by an additional month.\nThis time extension led to an initial divergence of the metabolomic profiles, but gradual convergence thereafter. The question that arises is whether the final metabolic profile of metabolic syndrome is unique, but the pathways leading to it differ. What is the degree of success of each model in terms of the 5 key features of metabolic syndrome. Regarding the experimental design. The study included two different dietary models to induce metabolic syndrome in rats. The samples were analyzed at various time points (5) metabolomic analysis and biochemical markers. The data collected include hematological, biochemical and metabolomic measurements in blood.\n\n\nData collection occurred in monthly intervals:\nTime point 0: Baseline or pre-treatment\nTime point 1: 1 month after nutrition plan treatment\nTime point 2: 2 months after nutrition plan treatment\nTime point 3: 3 months after nutrition plan treatment\nTime point 4: 3 months after nutrition plan treatment (same as time point 3) but post-mortem measurements using a different blood sample extraction method than in the other time points.\nThe post-mortem clinical data i.e.¬†weight, LDL, triglycerides etc. correspond to time point 4, and therefore match the metabolite data at time point 4. The match will be used to derive surrogate or substitute response variables (from the list of metabolites) for each variable of interest in the clinical data, since for the clinical data there is only 1 measurement in time. This is further described in the modeling page.\nTime point 4 will be excluded from the longitudinal analysis since it was post-mortem.\nAt time point 0 there were differences in the age of rats, and those differences are currently not known. At time point 1, these age differences were corrected by sampling the rat measurements asynchronously. Hence and since time will be a covariate in all models, age is not considered as a covariate i.e.¬†proportional to time since all rats have same age from time point 1. In addition, in order to correct for age differences at time point 0, the models will adjust for metabolites at time point 0.\n\n\n\n\n\n\n\n\n\n\n\nFigure¬†1: Missing values per variable, sorted by the percetange to the total 169 observations. Ten metabolites have more than 20% of their values missing.\n\n\n\n\n\n¬†\n\n\n\n\n\ncase\nmetabolite\n% missing\n\n\n\n\n1\nTheobromine\n53\n\n\n2\nSorbitol\n42\n\n\n3\n4OHProline\n39\n\n\n4\nPyroglutamic\n38\n\n\n5\nInositol\n36\n\n\n6\nGlycolic\n35\n\n\n7\ng_aminobutyric\n29\n\n\n8\nHippuric_Acid\n27\n\n\n9\nHomocysteine\n23\n\n\n\n\n\n¬†\n\n\n\n\n\n\n\n\nFigure¬†2: Missing values per data column.\n\n\n\n\n\n¬†\n¬†\n¬†\n\n\n\n\n\n\n\n\nFigure¬†3: Metabolite concentraion values in data. 0-1 scaled.\n\n\n\n\n\nThe missing values as seen in the data summaries above have been imputed with the value 1 so that the log transformation will result in a 0 value i.e.¬†non-detection. All below data descriptions, statistical tests and graphics are based on the imputed data. The Modeling page also utilizes the data after imputation.\n\n\n\n\n\n\n\n\n\n\nContinuousCategorical\n\n\n\n\n\n  \n    \n    \n    \n    \n    \n    \n    \n    \n    \n    \n    \n  \n  \n    \n      Metabolite Data Descriptives\n    \n    \n      75 Continous Variables of 79 Variables, 135 Observations\n    \n    \n      Variable\n      Label\n      n\n      Missing\n      Distinct\n      Info\n      Mean\n      pMedian\n      Gini‚Äâ|Œî|\n       \n      Quantiles .05  .10  .25  .50  .75  .90  .95 \n    \n  \n  \n    Methylamine\n\n134\n1\n134\n1\n423.4\n357.3\n429.6\n\n\n  19.96    54.88    117.34    271.28    624.71    1078.86    1336.83  \n    Dimethylamine\n\n129\n6\n129\n1\n661.5\n621.7\n570.2\n\n\n  38.83    49.98    90.15    712.11    983.96    1201.95    1403.78  \n    Trimethylamine\n\n127\n8\n127\n1\n955.3\n794.2\n1066\n\n\n  96.51    106.26    163.31    495.52    1457.89    2322.45    3245.75  \n    Glycine\n\n134\n1\n134\n1\n1146\n1030\n746.1\n\n\n  338.9    440.4    677.6    945.8    1358.5    1996.9    2673.4  \n    Trimethylamine_n_oxide\n\n135\n0\n135\n1\n48166\n46355\n34016\n\n\n  10777    14390    24213    41464    67779    87789    96621  \n    Monoisoamylamine\n\n126\n9\n126\n1\n3281\n2672\n3508\n\n\n  61.75    84.39    810.01    2373.42    4203.47    7197.61    9077.04  \n    Putrescine\n\n126\n9\n126\n1\n31378\n30689\n29503\n\n\n  376.6    707.6    1831.4    35904.2    54323.1    63496.5    67917.3  \n    Sarcosine\n\n135\n0\n135\n1\n219714\n219488\n75708\n\n\n  113222    130065    179555    218566    259775    299938    322061  \n    Alanine\n\n135\n0\n135\n1\n181962\n181746\n61484\n\n\n  94170    109583    151493    180672    219886    244448    259827  \n    Cadaverine\n\n119\n16\n119\n1\n194.4\n145.2\n198.2\n\n\n  35.23    42.54    62.17    112.22    248.19    457.80    634.20  \n    Choline\n\n134\n1\n134\n1\n1962193\n1985092\n472384\n\n\n  1065086    1548304    1758390    1985070    2216581    2519395    2544897  \n    g_aminobutyric\n\n96\n39\n96\n1\n689.4\n657.4\n571.6\n\n\n  40.63    69.75    244.99    599.85    1074.41    1405.05    1623.81  \n    Serine\n\n135\n0\n135\n1\n38727\n39120\n15305\n\n\n  13455    20391    29198    39964    46814    55177    60405  \n    Hypotaurine\n\n135\n0\n135\n1\n2960\n2912\n1425\n\n\n  1167    1400    2073    2902    3853    4551    5152  \n    Cytosine\n\n135\n0\n135\n1\n175653\n180133\n60499\n\n\n  71715    100766    148677    183875    213159    234218    246187  \n    Histamine\n\n135\n0\n135\n1\n39717\n31960\n29107\n\n\n  12252    17374    23339    29468    41992    68414    94916  \n    Uracil\n\n134\n1\n134\n1\n7268\n7200\n3879\n\n\n  1912    2893    4650    7204    9862    11483    12005  \n    Creatinine\n\n134\n1\n134\n1\n664888\n596593\n387868\n\n\n  283107    323613    430717    559742    767459    1118355    1283245  \n    Proline\n\n135\n0\n135\n1\n12101\n11901\n5532\n\n\n  5308    6379    8208    12161    14969    19100    21437  \n    Betaine\n\n135\n0\n135\n1\n4275341\n4273391\n1252705\n\n\n  2183312    3196544    3633436    4193768    4973552    5735604    6177199  \n    Norvaline_Valine\n\n135\n0\n135\n1\n282669\n281984\n99595\n\n\n  160441    183282    228670    277629    335779    394766    421021  \n    Threonine\n\n120\n15\n120\n1\n82928\n81463\n41940\n\n\n  32052    41163    54895    79966    105511    127745    154904  \n    Taurine\n\n135\n0\n135\n1\n17216\n17331\n7049\n\n\n  7798    9609    12465    17760    21777    24507    27234  \n    Thymine\n\n135\n0\n135\n1\n5796\n6107\n2061\n\n\n  1081    2472    5218    6199    7134    7633    8124  \n    Pyroglutamic\n\n84\n51\n84\n1\n3763\n2860\n5550\n\n\n  11.31    19.08    54.36    227.94    8304.96    14344.44    15495.60  \n    4OHProline\n\n83\n52\n83\n1\n2298\n2172\n2304\n\n\n  95.52    201.01    380.70    1550.49    3896.50    4806.33    5992.20  \n    Isoleucine\n\n135\n0\n135\n1\n34665\n34943\n12080\n\n\n  14403    20937    29468    34867    40411    49093    51891  \n    Leucine\n\n135\n0\n135\n1\n911203\n889770\n549270\n\n\n  282286    364043    521033    821633    1276641    1554380    1842392  \n    Creatine\n\n135\n0\n135\n1\n850572\n863036\n280966\n\n\n  377778    545055    725328    864268    1005066    1127007    1218109  \n    Asparagine\n\n135\n0\n135\n1\n8943\n8568\n5225\n\n\n  2664    3627    5613    8494    11664    15325    17632  \n    Aspartic_Acid\n\n135\n0\n135\n1\n1773\n1715\n1997\n\n\n  39.96    69.65    153.67    923.68    3253.44    4085.23    5324.57  \n    Adenine\n\n135\n0\n135\n1\n103095\n97434\n68946\n\n\n  12758    35063    58661    97296    132366    178952    209281  \n    Hypoxanthine\n\n134\n1\n134\n1\n936038\n918138\n671574\n\n\n  121502    206919    445774    919651    1366879    1740503    1931342  \n    Anthranilic\n\n116\n19\n116\n1\n736.4\n727.5\n364.7\n\n\n  207.1    316.8    537.4    719.3    953.9    1122.2    1254.7  \n    Glutamine\n\n135\n0\n135\n1\n458006\n439093\n290788\n\n\n  124442    190326    247251    378888    610074    795510    1001633  \n    Lysine\n\n129\n6\n129\n1\n69861\n69889\n75607\n\n\n  744.9    937.6    1678.4    61231.9    126306.9    160549.3    178740.8  \n    Methionine\n\n135\n0\n135\n1\n29887\n28032\n11730\n\n\n  16347    19550    23448    26738    32933    47610    53560  \n    Guanine\n\n110\n25\n110\n1\n22.21\n19.12\n21.56\n\n\n  2.100    3.044    6.374    14.614    30.756    51.083    64.624  \n    Xanthine\n\n131\n4\n131\n1\n41967\n41718\n25829\n\n\n  7433    11655    24411    41070    58730    71539    78269  \n    Allantoin\n\n133\n2\n133\n1\n21337\n21257\n8417\n\n\n  6522    12899    17130    21042    25588    28610    30992  \n    Tryptamine\n\n129\n6\n129\n1\n28.62\n24.79\n25.36\n\n\n  4.105    5.946    10.531    22.130    35.508    57.258    65.890  \n    Phenylalanine\n\n135\n0\n135\n1\n516449\n508093\n166958\n\n\n  263522    349229    438825    498913    587719    708804    785229  \n    3_Methylhistidine\n\n135\n0\n135\n1\n29800\n27832\n29823\n\n\n  810.5    1788.8    6341.4    23229.2    47803.1    61226.2    70634.8  \n    Cotinine\n\n135\n0\n135\n1\n19034\n18915\n12927\n\n\n  2243    4656    9052    18179    28519    34334    37667  \n    Fructose\n\n134\n1\n134\n1\n2471\n2452\n971.3\n\n\n  1117    1457    1950    2460    2924    3518    3812  \n    Theobromine\n\n63\n72\n63\n1\n27.46\n22.49\n26.79\n\n\n  2.196    4.243    9.492    16.884    36.399    71.577    84.793  \n    Tyrosine\n\n135\n0\n135\n1\n24594\n24055\n11224\n\n\n  12336    14112    16597    22589    31604    37578    42225  \n    Mannitol\n\n124\n11\n124\n1\n76.84\n70.37\n63.84\n\n\n  3.253    8.234    33.605    63.437    105.467    155.582    200.262  \n    Caffeine\n\n130\n5\n130\n1\n79.59\n71.97\n69.01\n\n\n  6.41    12.10    31.78    62.95    111.22    145.85    166.13  \n    Acetylcarnitine\n\n135\n0\n135\n1\n3887604\n3851093\n1272483\n\n\n  2406126    2623392    3072928    3737604    4649211    5433679    5872830  \n    Tryptophan\n\n135\n0\n135\n1\n82197\n81686\n29116\n\n\n  45697    52842    62781    84660    100089    112871    122827  \n    Indole_3_Lactic_Acid\n\n127\n8\n127\n1\n43.47\n38.71\n44.44\n\n\n  1.888    2.876    7.343    30.058    66.568    102.035    112.959  \n    Xanthurenic_Acid\n\n115\n20\n115\n1\n81.03\n82.95\n87.55\n\n\n  4.299    5.071    7.771    25.750    156.723    183.876    213.303  \n    5OH_L_Tryptophan\n\n134\n1\n134\n1\n101.7\n100\n40.94\n\n\n  47.50    60.16    80.11    99.30    122.08    150.67    171.81  \n    Thymidine\n\n134\n1\n134\n1\n16919\n17596\n5440\n\n\n  5560    9781    15367    17913    19929    22369    23469  \n    Cytidine\n\n135\n0\n135\n1\n34627\n30424\n33932\n\n\n  8446    9509    10901    15049    53533    77398    116167  \n    Adenosine\n\n133\n2\n133\n1\n539474\n509577\n372788\n\n\n  42119    178147    301811    492637    719130    953744    1113718  \n    Inosine\n\n134\n1\n134\n1\n18941\n18063\n8840\n\n\n  8832    10507    13175    17650    23421    30479    35001  \n    Lactose\n\n123\n12\n123\n1\n44.23\n33.64\n42.9\n\n\n  8.522    9.535    15.714    26.728    59.258    105.604    140.334  \n    Glycolic\n\n88\n47\n88\n1\n12.72\n8.368\n16.61\n\n\n  0.3601    0.6285    1.6980    3.2760    21.9630    41.4577    46.2001  \n    Pyruvic\n\n133\n2\n133\n1\n2086\n2072\n1048\n\n\n  620.8    964.2    1394.3    2092.1    2749.9    3134.6    3656.0  \n    Lactic_Acid\n\n135\n0\n135\n1\n2580\n2591\n1304\n\n\n  590.1    1123.1    1908.5    2550.7    3342.8    4152.8    4502.2  \n    Benzoic_Acid\n\n134\n1\n134\n1\n20.6\n20.76\n7.334\n\n\n  10.20    12.28    17.22    21.21    24.04    29.56    31.51  \n    Homocysteine\n\n104\n31\n104\n1\n11.36\n9.398\n12.06\n\n\n  0.2510    0.5294    3.0005    7.8310    16.2197    30.1079    35.3650  \n    Ribose\n\n135\n0\n135\n1\n58.64\n38.9\n71.37\n\n\n  4.110    5.716    9.588    22.547    78.739    182.974    227.937  \n    Xylitol\n\n113\n22\n113\n1\n4.569\n3.896\n4.647\n\n\n  0.3224    0.4902    1.2120    2.7670    6.4430    11.4452    13.9886  \n    Arabitol\n\n111\n24\n110\n1\n3.359\n2.955\n3.298\n\n\n  0.1960    0.3210    0.9495    2.3630    4.8680    7.6020    9.7850  \n    Ascorbic_Acid\n\n134\n1\n134\n1\n45.19\n44.39\n36.67\n\n\n  1.793    3.345    15.849    45.382    66.610    94.125    102.456  \n    Hippuric_Acid\n\n98\n37\n98\n1\n105.6\n90.96\n145.2\n\n\n  0.2394    0.6285    1.7450    9.0705    198.7158    315.3347    398.7045  \n    Glucose\n\n135\n0\n135\n1\n1790\n1829\n640.5\n\n\n  645.1    988.1    1503.6    1860.6    2151.0    2412.0    2558.7  \n    Mannose\n\n134\n1\n134\n1\n2178\n2290\n1017\n\n\n  375.7    515.2    1773.7    2419.1    2765.3    3160.9    3444.0  \n    Inositol\n\n87\n48\n87\n1\n7.221\n3.821\n9.558\n\n\n  0.2215    0.4726    1.0235    2.5620    7.1655    23.7392    31.3565  \n    Sorbitol\n\n78\n57\n77\n1\n8.037\n3.296\n11.04\n\n\n  0.1477    0.2143    0.7765    2.1340    5.7780    29.2574    32.9332  \n    Uridine\n\n135\n0\n135\n1\n1944\n1954\n914.3\n\n\n  227.1    997.3    1493.6    1950.0    2484.3    2856.8    3327.7  \n    Maltose\n\n110\n25\n110\n1\n6.544\n5.446\n6.76\n\n\n  0.3386    0.7923    1.6010    4.1180    8.7125    15.7619    19.3221  \n  \n  \n  \n\n\n\n\n\n\n\n  \n    \n      Metabolite Data Descriptives\n    \n    \n      4 Categorical Variables of 79 Variables, 135 Observations\n    \n    \n      Variable\n      Label\n      n\n      Missing\n      Distinct\n      Info\n      Mean\n      pMedian\n      Gini‚Äâ|Œî|\n       \n    \n  \n  \n    ID\n\n135\n0\n34\n\n\n\n\n\n\n    Time_Point\nWeek in treatment\n135\n0\n4\n0.938\n1.496\n1.5\n1.263\n\n\n    NutrMod\nNutritional Model: Controls (normal diet), HC (high carbs diet) and  HFHC (high fat and high carb diet)\n135\n0\n3\n\n\n\n\n\n\n    Month\n\n135\n0\n4\n0.938\n1.496\n1.5\n1.263\n\n\n  \n  \n  \n\n\n\n\n\n\n\n\nMetabolic syndrome is associated with several metabolites that reflect alterations in glucose, lipid, amino acid, and energy metabolism. Key metabolites include:\n\nLipid Metabolites\n\nTriglycerides (TG): Elevated in metabolic syndrome, indicating impaired fat metabolism. Free fatty acids (FFA): Increased levels contribute to insulin resistance and inflammation. Low-density lipoprotein (LDL) and Very-low-density lipoprotein (VLDL): Higher levels of these ‚Äúbad‚Äù cholesterol types are common. High-density lipoprotein (HDL): Reduced ‚Äúgood‚Äù cholesterol levels are a marker of metabolic syndrome. Ceramides: Bioactive lipids linked to insulin resistance and cardiovascular disease.\n\nGlucose and Energy Metabolites\n\nGlucose: Elevated fasting glucose is a diagnostic marker of metabolic syndrome. Insulin: High levels indicate insulin resistance. Lactate: Increased due to altered glycolysis and mitochondrial dysfunction. Ketone bodies (Œ≤-hydroxybutyrate, acetoacetate): Altered levels indicate disrupted fatty acid oxidation.\n\nAmino Acid Metabolites\n\nBranched-chain amino acids (BCAAs) (Leucine, Isoleucine, Valine): Elevated levels are strongly linked to insulin resistance. Aromatic amino acids (Tyrosine, Phenylalanine): Increased levels are associated with obesity and diabetes risk. Glutamate and Glutamine: Higher glutamate and lower glutamine levels are associated with metabolic dysfunction.\n\nInflammatory and Oxidative Stress Metabolites\n\nC-reactive protein (CRP): A marker of systemic inflammation. Homocysteine: Elevated levels are linked to cardiovascular risk. Oxidized LDL: A marker of oxidative stress and atherosclerosis risk.\n\nGut Microbiome-Derived Metabolites\n\nShort-chain fatty acids (SCFAs) (Butyrate, Acetate, Propionate): Reduced levels may indicate an unhealthy gut microbiome. Trimethylamine-N-oxide (TMAO): Elevated levels are associated with cardiovascular disease risk. These metabolites collectively indicate metabolic dysfunction, insulin resistance, and increased cardiovascular risk. Monitoring and targeting these biomarkers through diet, exercise, and medications can help manage metabolic syndrome.\n‚úÖ Strongly Associated Biomarkers for Metabolic Syndrome:\n\nTrimethylamine N-oxide (TMAO) ‚Äì Elevated levels are linked to cardiovascular disease, insulin resistance, and gut microbiota imbalance.\nCholine ‚Äì Essential for lipid metabolism; imbalances are linked to NAFLD and insulin resistance.\nSerine ‚Äì Low levels are associated with insulin resistance and metabolic dysfunction.\nGlycine ‚Äì Reduced in MetS; involved in antioxidant defense and glucose metabolism.\nAlanine ‚Äì Increased in MetS; involved in gluconeogenesis and insulin resistance.\nIsoleucine ‚Äì Branched-chain amino acid (BCAA) associated with obesity, insulin resistance, and metabolic dysfunction.\nLeucine ‚Äì Elevated levels correlate with MetS, obesity, and T2D.\nCreatinine ‚Äì A marker of muscle metabolism and kidney function, associated with insulin resistance and MetS progression.\nTaurine ‚Äì Linked to lipid metabolism, blood pressure regulation, and oxidative stress.\nBetaine ‚Äì Plays a role in homocysteine metabolism; imbalances can contribute to cardiovascular risk.\nTyrosine ‚Äì Elevated in insulin resistance and metabolic dysfunction.\nPhenylalanine ‚Äì Increased in MetS, linked to impaired glucose metabolism.\nAcetylcarnitine ‚Äì Implicated in fatty acid metabolism dysfunction in MetS.\nFructose ‚Äì High intake contributes to insulin resistance and fatty liver disease.\nGlucose ‚Äì A core biomarker of insulin resistance and diabetes.\nMannose ‚Äì Altered metabolism is linked to insulin resistance.\nLactic Acid ‚Äì Increased in mitochondrial dysfunction and metabolic disorders.\nPyruvic Acid (Pyruvate) ‚Äì Involved in glycolysis; alterations signal metabolic dysfunction.\n\nüü° Moderately Associated Biomarkers (Need Further Validation):\n\nPutrescine & Cadaverine ‚Äì Polyamines linked to gut microbiota and inflammation in MetS.\nSarcosine ‚Äì Related to methylation and lipid metabolism, but its role in MetS is unclear.\nHistamine ‚Äì Involved in inflammatory responses and metabolic homeostasis.\nHypotaurine ‚Äì Precursor to taurine; may help counter oxidative stress in MetS.\nAsparagine ‚Äì Altered levels may reflect amino acid metabolism changes in MetS.\nAspartic Acid ‚Äì May be involved in energy metabolism and oxidative stress.\nMethionine ‚Äì Essential for methylation reactions; altered levels may affect lipid metabolism.\nLysine ‚Äì Essential amino acid; its metabolic disturbances could relate to insulin resistance.\nAnthranilic Acid ‚Äì A metabolite of tryptophan linked to inflammation and gut microbiota.\nIndole-3-Lactic Acid ‚Äì Gut-derived metabolite with possible metabolic and inflammatory implications.\n5-Hydroxy-L-Tryptophan (5OH-L-Tryptophan) ‚Äì A serotonin precursor involved in neuroendocrine and metabolic regulation.\nXanthurenic Acid ‚Äì A tryptophan metabolite associated with insulin resistance and oxidative stress.\nBenzoic Acid ‚Äì Related to gut microbiota metabolism, possibly linked to MetS.\nXanthine & Hypoxanthine ‚Äì Purine metabolism intermediates; increased levels may be linked to oxidative stress and insulin resistance.\n\n‚ùå Less Relevant or Weak Evidence for MetS:\nThese metabolites are less directly linked to metabolic syndrome but may still have indirect roles:\n\nMethylamine, Dimethylamine, Trimethylamine ‚Äì Related to gut metabolism but not primary MetS markers. Monoisoamylamine ‚Äì Limited data on its role in MetS.\nCytosine, Uracil, Thymine, Adenine, Guanine, Cytidine, Thymidine, Adenosine, Inosine, Uridine, Maltose, Ribose, Xylitol, Arabitol ‚Äì These are nucleotides and sugars with limited direct associations to MetS.\nCaffeine ‚Äì May have protective effects against MetS but is not a biomarker.\nCotinine ‚Äì A nicotine metabolite, not directly related to MetS.\nMannitol, Lactose, Ascorbic Acid (Vitamin C) ‚Äì Not considered primary biomarkers for MetS.\n\nüìå Summary:\nStrongest biomarkers: TMAO, Choline, Serine, Glycine, Alanine, BCAAs (Isoleucine, Leucine), Taurine, Betaine, Acetylcarnitine, Glucose, Lactic Acid, Fructose.\nModerate biomarkers: Polyamines (Putrescine, Cadaverine), Tryptophan metabolites, Histamine, Hypotaurine.\nLess relevant metabolites: Nucleotides, sugar alcohols, caffeine.\n\n\n\n\nüìå Summary: Best Predictors of TMAO\nüî• Strongest Predictors: Choline, Betaine, Carnitine (Acetylcarnitine), Trimethylamine, Dimethylamine, Methylamine\nüü° Moderate Predictors: Serine, Methionine, Glycine, Taurine, Creatinine, Histamine, Hypotaurine\n‚ö†Ô∏è Weaker Indirect Predictors: Fructose, Glucose, Lactic Acid, Pyruvic Acid, Xanthurenic Acid, Putrescine, Cadaverine\n\n\n\nüìå Summary: Best Predictors of Choline\nüî• Strongest Predictors: Betaine, Serine, Methionine, Glycine, Acetylcarnitine\nüü° Moderate Predictors: Trimethylamine, Dimethylamine, Methylamine, Taurine, Histamine, Creatinine\n‚ö†Ô∏è Weaker Indirect Predictors: Fructose, Glucose, Lactic Acid, Pyruvic Acid, Xanthurenic Acid, Putrescine, Cadaverine\n\n\n\nüìå Summary: Best Predictors of Serine\nüî• Strongest Predictors: Glycine, Methionine, Asparagine, Aspartic Acid, Glutamine, Pyruvic Acid\nüü° Moderate Predictors: Choline, Betaine, Taurine, Histamine, Lactic Acid\n‚ö†Ô∏è Weaker Indirect Predictors: Fructose, Glucose, Xanthurenic Acid, Putrescine, Cadaverine, Creatinine\n\n\n\nüìå Summary: Best Predictors of Glycine\nüî• Strongest Predictors: Serine, Methionine, Choline, Betaine, Glutamine, Aspartic Acid\nüü° Moderate Predictors: Taurine, Histamine, Acetylcarnitine, Creatinine, Lactic Acid\n‚ö†Ô∏è Weaker Indirect Predictors: Fructose, Glucose, Xanthurenic Acid, Putrescine, Cadaverine, Phenylalanine\n\n\n\nüìå Summary: Best Predictors of Alanine\nüî• Strongest Predictors: Pyruvic Acid, Aspartic Acid, Glutamine, Glutamate, Lactic Acid, Asparagine\nüü° Moderate Predictors: Serine, Glycine, Methionine, Creatinine, Glucose, Fructose\n‚ö†Ô∏è Weaker Indirect Predictors: Xanthurenic Acid, Putrescine, Cadaverine, Phenylalanine, Taurine\n\n\n\nüìå Summary: Best Predictors of Isoleucine\nüî• Strongest Predictors: Leucine, Valine, Aspartic Acid, Glutamine, Pyruvic Acid\nüü° Moderate Predictors: Alanine, Serine, Methionine, Creatinine, Lactic Acid, Glucose\n‚ö†Ô∏è Weaker Indirect Predictors: Histamine, Taurine, Xanthurenic Acid, Putrescine, Fructose\n\n\n\nüìå Summary: Best Predictors of Leucine\nüî• Strongest Predictors: Isoleucine, Valine, Aspartic Acid, Glutamine, Pyruvic Acid\nüü° Moderate Predictors: Alanine, Serine, Methionine, Creatinine, Lactic Acid, Glucose\n‚ö†Ô∏è Weaker Indirect Predictors: Histamine, Taurine, Xanthurenic Acid, Putrescine, Fructose\n\n\n\nüìå Summary: Best Predictors of Creatinine\nüî• Strongest Predictors: Creatine, Isoleucine, Leucine, Alanine, Glutamine, Glutamate\nüü° Moderate Predictors: Valine, Methionine, Aspartic Acid, Pyruvic Acid, Lactic Acid, Glucose, Fructose\n‚ö†Ô∏è Weaker Indirect Predictors: Histamine, Taurine, Xanthurenic Acid, Putrescine, Mannose, Ribose\n\n\n\nüìå Summary: Best Predictors of Taurine\nüî• Strongest Predictors: Methionine, Hypotaurine, Glutamine, Glutamate, Aspartic Acid\nüü° Moderate Predictors: Serine, Alanine, Creatinine, Glucose, Fructose, Lactic Acid, Pyruvic Acid\n‚ö†Ô∏è Weaker Indirect Predictors: Histamine, Xanthurenic Acid, Putrescine, Mannose, Ribose\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\nFigure¬†4: Correlation plot of metabolites considering all time points and nutrition models. In general the correlations are positive and high, which might be expected as the majority of data points correspond to one of the two nutrition models i.e.¬†metabolite concentrations are overall affected by the diet treatment.\n\n\n\n\n\n\n\n\nNote that p-values shown below are FDR adjusted at \\(a = 0.2\\) for all nutritional model comparisons i.e.¬†FDR_algc-adj, but not for any metabolite data (see modeling page for this).\n\n\nNotable cases: [[plot_number]] Metabolite:\n\n[[11]] Choline\n[[12]] g_aminobutyric\n[[14]] Hypotaurine\n[[18]] Creatinine\n[[21]] Norvaline_Valine\n[[23]] Taurine\n[[28]] Leucine\n[[33]] Hypoxanthine\n[[42]] Phenylalanine\n[[51]] Tryptophan\n[[55]] Thymidine\n\n\n\n[[1]]\n\n\n\n\n\n\n\n\n\n\n[[2]]\n\n\n\n\n\n\n\n\n\n\n[[3]]\n\n\n\n\n\n\n\n\n\n\n[[4]]\n\n\n\n\n\n\n\n\n\n\n[[5]]\n\n\n\n\n\n\n\n\n\n\n[[6]]\n\n\n\n\n\n\n\n\n\n\n[[7]]\n\n\n\n\n\n\n\n\n\n\n[[8]]\n\n\n\n\n\n\n\n\n\n\n[[9]]\n\n\n\n\n\n\n\n\n\n\n[[10]]\n\n\n\n\n\n\n\n\n\n\n[[11]]\n\n\n\n\n\n\n\n\n\n\n[[12]]\n\n\n\n\n\n\n\n\n\n\n[[13]]\n\n\n\n\n\n\n\n\n\n\n[[14]]\n\n\n\n\n\n\n\n\n\n\n[[15]]\n\n\n\n\n\n\n\n\n\n\n[[16]]\n\n\n\n\n\n\n\n\n\n\n[[17]]\n\n\n\n\n\n\n\n\n\n\n[[18]]\n\n\n\n\n\n\n\n\n\n\n[[19]]\n\n\n\n\n\n\n\n\n\n\n[[20]]\n\n\n\n\n\n\n\n\n\n\n[[21]]\n\n\n\n\n\n\n\n\n\n\n[[22]]\n\n\n\n\n\n\n\n\n\n\n[[23]]\n\n\n\n\n\n\n\n\n\n\n[[24]]\n\n\n\n\n\n\n\n\n\n\n[[25]]\n\n\n\n\n\n\n\n\n\n\n[[26]]\n\n\n\n\n\n\n\n\n\n\n[[27]]\n\n\n\n\n\n\n\n\n\n\n[[28]]\n\n\n\n\n\n\n\n\n\n\n[[29]]\n\n\n\n\n\n\n\n\n\n\n[[30]]\n\n\n\n\n\n\n\n\n\n\n[[31]]\n\n\n\n\n\n\n\n\n\n\n[[32]]\n\n\n\n\n\n\n\n\n\n\n[[33]]\n\n\n\n\n\n\n\n\n\n\n[[34]]\n\n\n\n\n\n\n\n\n\n\n[[35]]\n\n\n\n\n\n\n\n\n\n\n[[36]]\n\n\n\n\n\n\n\n\n\n\n[[37]]\n\n\n\n\n\n\n\n\n\n\n[[38]]\n\n\n\n\n\n\n\n\n\n\n[[39]]\n\n\n\n\n\n\n\n\n\n\n[[40]]\n\n\n\n\n\n\n\n\n\n\n[[41]]\n\n\n\n\n\n\n\n\n\n\n[[42]]\n\n\n\n\n\n\n\n\n\n\n[[43]]\n\n\n\n\n\n\n\n\n\n\n[[44]]\n\n\n\n\n\n\n\n\n\n\n[[45]]\n\n\n\n\n\n\n\n\n\n\n[[46]]\n\n\n\n\n\n\n\n\n\n\n[[47]]\n\n\n\n\n\n\n\n\n\n\n[[48]]\n\n\n\n\n\n\n\n\n\n\n[[49]]\n\n\n\n\n\n\n\n\n\n\n[[50]]\n\n\n\n\n\n\n\n\n\n\n[[51]]\n\n\n\n\n\n\n\n\n\n\n[[52]]\n\n\n\n\n\n\n\n\n\n\n[[53]]\n\n\n\n\n\n\n\n\n\n\n[[54]]\n\n\n\n\n\n\n\n\n\n\n[[55]]\n\n\n\n\n\n\n\n\n\n\n[[56]]\n\n\n\n\n\n\n\n\n\n\n[[57]]\n\n\n\n\n\n\n\n\n\n\n[[58]]\n\n\n\n\n\n\n\n\n\n\n[[59]]\n\n\n\n\n\n\n\n\n\n\n[[60]]\n\n\n\n\n\n\n\n\n\n\n[[61]]\n\n\n\n\n\n\n\n\n\n\n[[62]]\n\n\n\n\n\n\n\n\n\n\n[[63]]\n\n\n\n\n\n\n\n\n\n\n[[64]]\n\n\n\n\n\n\n\n\n\n\n[[65]]\n\n\n\n\n\n\n\n\n\n\n[[66]]\n\n\n\n\n\n\n\n\n\n\n[[67]]\n\n\n\n\n\n\n\n\n\n\n[[68]]\n\n\n\n\n\n\n\n\n\n\n[[69]]\n\n\n\n\n\n\n\n\n\n\n[[70]]\n\n\n\n\n\n\n\n\n\n\n[[71]]\n\n\n\n\n\n\n\n\n\n\n[[72]]\n\n\n\n\n\n\n\n\n\n\n[[73]]\n\n\n\n\n\n\n\n\n\n\n[[74]]\n\n\n\n\n\n\n\n\n\n\n[[75]]\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\nContinuousCategorical\n\n\n\n\n\n  \n    \n    \n    \n    \n    \n    \n    \n    \n    \n    \n    \n  \n  \n    \n      Clinical Data (post-mortem) Descriptives\n    \n    \n      22 Continous Variables of 25 Variables, 34 Observations\n    \n    \n      Variable\n      Label\n      n\n      Missing\n      Distinct\n      Info\n      Mean\n      pMedian\n      Gini‚Äâ|Œî|\n       \n      Quantiles .05  .10  .25  .50  .75  .90  .95 \n    \n  \n  \n    Glucose\n\n34\n0\n27\n0.999\n149.7\n146.5\n25.54\n\n\n  118.6    131.3    140.0    146.0    153.8    181.3    202.1  \n    Glucose_œÑŒ±ŒπŒΩŒØŒµœÇ\n\n34\n0\n23\n0.997\n136.9\n137.5\n13.55\n\n\n  114.2    125.3    131.0    139.0    143.0    149.7    154.7  \n    Weight\n\n34\n0\n30\n0.999\n468.4\n463.5\n48.08\n\n\n  414.0    422.3    435.0    458.5    487.2    515.4    549.3  \n    BUN\n\n34\n0\n18\n0.996\n35.56\n31.5\n13.05\n\n\n  25.65    26.00    28.00    31.00    34.75    38.40    42.75  \n    Uric_Œëcid\n\n34\n0\n13\n0.988\n1.318\n1.25\n0.4364\n\n\n  0.800    0.860    1.025    1.250    1.475    1.800    2.105  \n    Creatinine\n\n34\n0\n14\n0.985\n0.4924\n0.435\n0.1554\n\n\n  0.380    0.393    0.410    0.425    0.460    0.490    0.497  \n    Tchol\n\n34\n0\n30\n0.999\n126.1\n124.5\n35.94\n\n\n  86.25    91.30    97.75    125.00    148.75    160.80    180.15  \n    Triglycerides\n\n32\n2\n30\n1.000\n267\n243.8\n174.9\n\n\n  90.2    115.7    148.0    231.0    320.0    496.1    597.2  \n    HDL\n\n34\n0\n23\n0.998\n36.94\n36.5\n10.47\n\n\n  24.30    27.30    30.25    35.00    41.75    48.00    54.40  \n    LDL\n\n34\n0\n14\n0.987\n9.147\n9\n3.995\n\n\n  5.00    5.30    7.00    8.00    11.75    14.70    16.00  \n    VLDL\n\n34\n0\n28\n0.999\n52.97\n48.5\n34.5\n\n\n  18.25    23.30    29.25    46.00    65.25    95.00    118.75  \n    TGL_HDL_ratio\n\n32\n2\n31\n1.000\n7.588\n6.37\n5.321\n\n\n  2.776    3.390    4.330    5.600    8.508    12.689    15.953  \n    Atherogenic_Index\n\n32\n2\n27\n0.999\n0.7975\n0.78\n0.2801\n\n\n  0.4415    0.5310    0.6375    0.7500    0.9275    1.1000    1.2015  \n    AST\n\n34\n0\n31\n1.000\n116.1\n107.5\n48.4\n\n\n  72.30    74.30    87.25    102.00    125.75    157.70    189.95  \n    ALT\n\n34\n0\n25\n0.998\n36.59\n36.5\n12.15\n\n\n  23.3    24.0    27.0    37.0    43.0    49.7    52.7  \n    ALP\n\n34\n0\n30\n0.999\n130.9\n129\n41.33\n\n\n  90.65    91.30    100.50    121.50    159.00    185.40    188.10  \n    ALB\n\n34\n0\n11\n0.975\n3.324\n3.35\n0.2909\n\n\n  2.965    3.030    3.200    3.350    3.475    3.670    3.700  \n    FERRITIN\n\n34\n0\n34\n1.000\n7.151\n6.97\n2.973\n\n\n  3.903    4.061    5.380    6.610    8.705    10.425    11.817  \n    LDH\n\n34\n0\n31\n1.000\n567.9\n537\n210.7\n\n\n  336.6    369.3    450.8    520.0    627.8    872.5    993.8  \n    AMYLASE\n\n34\n0\n34\n1.000\n2119\n2136\n373.4\n\n\n  1578    1719    1916    2176    2358    2496    2564  \n    Mg\n\n34\n0\n29\n0.999\n2.833\n2.77\n0.3814\n\n\n  2.497    2.520    2.590    2.755    2.962    3.074    3.131  \n    D3\n\n34\n0\n33\n1.000\n41.5\n41.75\n6.52\n\n\n  31.97    33.26    38.75    41.85    45.88    48.94    49.24  \n  \n  \n  \n\n\n\n\n\n\n\n  \n    \n      Clinical Data (post-mortem) Descriptives\n    \n    \n      3 Categorical Variables of 25 Variables, 34 Observations\n    \n    \n      Variable\n      Label\n      n\n      Missing\n      Distinct\n      Info\n      Mean\n      pMedian\n      Gini‚Äâ|Œî|\n       \n    \n  \n  \n    ID\n\n34\n0\n34\n\n\n\n\n\n\n    NutrMod\n\n34\n0\n3\n0.876\n2.147\n2\n0.8574\n\n\n    Na\n\n34\n0\n9\n0.953\n145.3\n145\n2.005\n\n\n  \n  \n  \n\n\n\n\n\n\n\nNote that p-values shown below are FDR adjusted at \\(a = 0.2\\) for all nutritional model comparisons i.e.¬†FDR_algc-adj, but not for any metabolite data (see modeling page for this).\nNotable cases: [[plot_number]] Clinical Metric:\n\n[[7]] Tchol\n[[9]] HDL\n[[10]] LDL\n[[11]] VLDL\n[[15]] ALT\n[[16]] ALP\n[[20]] Amylase\n\n\n\n[[1]]\n\n\n\n\n\n\n\n\n\n\n[[2]]\n\n\n\n\n\n\n\n\n\n\n[[3]]\n\n\n\n\n\n\n\n\n\n\n[[4]]\n\n\n\n\n\n\n\n\n\n\n[[5]]\n\n\n\n\n\n\n\n\n\n\n[[6]]\n\n\n\n\n\n\n\n\n\n\n[[7]]\n\n\n\n\n\n\n\n\n\n\n[[8]]\n\n\n\n\n\n\n\n\n\n\n[[9]]\n\n\n\n\n\n\n\n\n\n\n[[10]]\n\n\n\n\n\n\n\n\n\n\n[[11]]\n\n\n\n\n\n\n\n\n\n\n[[12]]\n\n\n\n\n\n\n\n\n\n\n[[13]]\n\n\n\n\n\n\n\n\n\n\n[[14]]\n\n\n\n\n\n\n\n\n\n\n[[15]]\n\n\n\n\n\n\n\n\n\n\n[[16]]\n\n\n\n\n\n\n\n\n\n\n[[17]]\n\n\n\n\n\n\n\n\n\n\n[[18]]\n\n\n\n\n\n\n\n\n\n\n[[19]]\n\n\n\n\n\n\n\n\n\n\n[[20]]\n\n\n\n\n\n\n\n\n\n\n[[21]]\n\n\n\n\n\n\n\n\n\n\n[[22]]\n\n\n\n\n\n\n\n\n\n\n[[23]]\n\n\n\n\n\n\n\n\n\n\n\n\n\nNote that p-values shown below are FDR adjusted at \\(a = 0.05\\) for all nutritional model comparisons but separately for each metabolite.\n\n\n[[1]]\n\n\n\n\n\n\n\n\n\n\n[[2]]\n\n\n\n\n\n\n\n\n\n\n[[3]]\n\n\n\n\n\n\n\n\n\n\n[[4]]\n\n\n\n\n\n\n\n\n\n\n[[5]]\n\n\n\n\n\n\n\n\n\n\n[[6]]\n\n\n\n\n\n\n\n\n\n\n[[7]]\n\n\n\n\n\n\n\n\n\n\n[[8]]\n\n\n\n\n\n\n\n\n\n\n[[9]]\n\n\n\n\n\n\n\n\n\n\n[[10]]\n\n\n\n\n\n\n\n\n\n\n[[11]]\n\n\n\n\n\n\n\n\n\n\n[[12]]\n\n\n\n\n\n\n\n\n\n\n\n\nSee the Modeling page for both a univariate and multivariate analysis on lipids collected at post-mortem stage, as well as their differences amongst the nutritional models.",
    "crumbs": [
      "Sections",
      "Processing & EDA"
    ]
  },
  {
    "objectID": "data_metabolic_syndrome.html#notes-quick-descriptives",
    "href": "data_metabolic_syndrome.html#notes-quick-descriptives",
    "title": "Data Description/Processing - Metabolic Syndrome In Rats",
    "section": "",
    "text": "Data collection occurred in monthly intervals:\nTime point 0: Baseline or pre-treatment\nTime point 1: 1 month after nutrition plan treatment\nTime point 2: 2 months after nutrition plan treatment\nTime point 3: 3 months after nutrition plan treatment\nTime point 4: 3 months after nutrition plan treatment (same as time point 3) but post-mortem measurements using a different blood sample extraction method than in the other time points.\nThe post-mortem clinical data i.e.¬†weight, LDL, triglycerides etc. correspond to time point 4, and therefore match the metabolite data at time point 4. The match will be used to derive surrogate or substitute response variables (from the list of metabolites) for each variable of interest in the clinical data, since for the clinical data there is only 1 measurement in time. This is further described in the modeling page.\nTime point 4 will be excluded from the longitudinal analysis since it was post-mortem.\nAt time point 0 there were differences in the age of rats, and those differences are currently not known. At time point 1, these age differences were corrected by sampling the rat measurements asynchronously. Hence and since time will be a covariate in all models, age is not considered as a covariate i.e.¬†proportional to time since all rats have same age from time point 1. In addition, in order to correct for age differences at time point 0, the models will adjust for metabolites at time point 0.",
    "crumbs": [
      "Sections",
      "Processing & EDA"
    ]
  },
  {
    "objectID": "data_metabolic_syndrome.html#metabolite-data-imputation",
    "href": "data_metabolic_syndrome.html#metabolite-data-imputation",
    "title": "Data Description/Processing - Metabolic Syndrome In Rats",
    "section": "",
    "text": "Figure¬†1: Missing values per variable, sorted by the percetange to the total 169 observations. Ten metabolites have more than 20% of their values missing.\n\n\n\n\n\n¬†\n\n\n\n\n\ncase\nmetabolite\n% missing\n\n\n\n\n1\nTheobromine\n53\n\n\n2\nSorbitol\n42\n\n\n3\n4OHProline\n39\n\n\n4\nPyroglutamic\n38\n\n\n5\nInositol\n36\n\n\n6\nGlycolic\n35\n\n\n7\ng_aminobutyric\n29\n\n\n8\nHippuric_Acid\n27\n\n\n9\nHomocysteine\n23\n\n\n\n\n\n¬†\n\n\n\n\n\n\n\n\nFigure¬†2: Missing values per data column.\n\n\n\n\n\n¬†\n¬†\n¬†\n\n\n\n\n\n\n\n\nFigure¬†3: Metabolite concentraion values in data. 0-1 scaled.\n\n\n\n\n\nThe missing values as seen in the data summaries above have been imputed with the value 1 so that the log transformation will result in a 0 value i.e.¬†non-detection. All below data descriptions, statistical tests and graphics are based on the imputed data. The Modeling page also utilizes the data after imputation.",
    "crumbs": [
      "Sections",
      "Processing & EDA"
    ]
  },
  {
    "objectID": "data_metabolic_syndrome.html#metabolite-data-summaries",
    "href": "data_metabolic_syndrome.html#metabolite-data-summaries",
    "title": "Data Description/Processing - Metabolic Syndrome In Rats",
    "section": "",
    "text": "ContinuousCategorical\n\n\n\n\n\n  \n    \n    \n    \n    \n    \n    \n    \n    \n    \n    \n    \n  \n  \n    \n      Metabolite Data Descriptives\n    \n    \n      75 Continous Variables of 79 Variables, 135 Observations\n    \n    \n      Variable\n      Label\n      n\n      Missing\n      Distinct\n      Info\n      Mean\n      pMedian\n      Gini‚Äâ|Œî|\n       \n      Quantiles .05  .10  .25  .50  .75  .90  .95 \n    \n  \n  \n    Methylamine\n\n134\n1\n134\n1\n423.4\n357.3\n429.6\n\n\n  19.96    54.88    117.34    271.28    624.71    1078.86    1336.83  \n    Dimethylamine\n\n129\n6\n129\n1\n661.5\n621.7\n570.2\n\n\n  38.83    49.98    90.15    712.11    983.96    1201.95    1403.78  \n    Trimethylamine\n\n127\n8\n127\n1\n955.3\n794.2\n1066\n\n\n  96.51    106.26    163.31    495.52    1457.89    2322.45    3245.75  \n    Glycine\n\n134\n1\n134\n1\n1146\n1030\n746.1\n\n\n  338.9    440.4    677.6    945.8    1358.5    1996.9    2673.4  \n    Trimethylamine_n_oxide\n\n135\n0\n135\n1\n48166\n46355\n34016\n\n\n  10777    14390    24213    41464    67779    87789    96621  \n    Monoisoamylamine\n\n126\n9\n126\n1\n3281\n2672\n3508\n\n\n  61.75    84.39    810.01    2373.42    4203.47    7197.61    9077.04  \n    Putrescine\n\n126\n9\n126\n1\n31378\n30689\n29503\n\n\n  376.6    707.6    1831.4    35904.2    54323.1    63496.5    67917.3  \n    Sarcosine\n\n135\n0\n135\n1\n219714\n219488\n75708\n\n\n  113222    130065    179555    218566    259775    299938    322061  \n    Alanine\n\n135\n0\n135\n1\n181962\n181746\n61484\n\n\n  94170    109583    151493    180672    219886    244448    259827  \n    Cadaverine\n\n119\n16\n119\n1\n194.4\n145.2\n198.2\n\n\n  35.23    42.54    62.17    112.22    248.19    457.80    634.20  \n    Choline\n\n134\n1\n134\n1\n1962193\n1985092\n472384\n\n\n  1065086    1548304    1758390    1985070    2216581    2519395    2544897  \n    g_aminobutyric\n\n96\n39\n96\n1\n689.4\n657.4\n571.6\n\n\n  40.63    69.75    244.99    599.85    1074.41    1405.05    1623.81  \n    Serine\n\n135\n0\n135\n1\n38727\n39120\n15305\n\n\n  13455    20391    29198    39964    46814    55177    60405  \n    Hypotaurine\n\n135\n0\n135\n1\n2960\n2912\n1425\n\n\n  1167    1400    2073    2902    3853    4551    5152  \n    Cytosine\n\n135\n0\n135\n1\n175653\n180133\n60499\n\n\n  71715    100766    148677    183875    213159    234218    246187  \n    Histamine\n\n135\n0\n135\n1\n39717\n31960\n29107\n\n\n  12252    17374    23339    29468    41992    68414    94916  \n    Uracil\n\n134\n1\n134\n1\n7268\n7200\n3879\n\n\n  1912    2893    4650    7204    9862    11483    12005  \n    Creatinine\n\n134\n1\n134\n1\n664888\n596593\n387868\n\n\n  283107    323613    430717    559742    767459    1118355    1283245  \n    Proline\n\n135\n0\n135\n1\n12101\n11901\n5532\n\n\n  5308    6379    8208    12161    14969    19100    21437  \n    Betaine\n\n135\n0\n135\n1\n4275341\n4273391\n1252705\n\n\n  2183312    3196544    3633436    4193768    4973552    5735604    6177199  \n    Norvaline_Valine\n\n135\n0\n135\n1\n282669\n281984\n99595\n\n\n  160441    183282    228670    277629    335779    394766    421021  \n    Threonine\n\n120\n15\n120\n1\n82928\n81463\n41940\n\n\n  32052    41163    54895    79966    105511    127745    154904  \n    Taurine\n\n135\n0\n135\n1\n17216\n17331\n7049\n\n\n  7798    9609    12465    17760    21777    24507    27234  \n    Thymine\n\n135\n0\n135\n1\n5796\n6107\n2061\n\n\n  1081    2472    5218    6199    7134    7633    8124  \n    Pyroglutamic\n\n84\n51\n84\n1\n3763\n2860\n5550\n\n\n  11.31    19.08    54.36    227.94    8304.96    14344.44    15495.60  \n    4OHProline\n\n83\n52\n83\n1\n2298\n2172\n2304\n\n\n  95.52    201.01    380.70    1550.49    3896.50    4806.33    5992.20  \n    Isoleucine\n\n135\n0\n135\n1\n34665\n34943\n12080\n\n\n  14403    20937    29468    34867    40411    49093    51891  \n    Leucine\n\n135\n0\n135\n1\n911203\n889770\n549270\n\n\n  282286    364043    521033    821633    1276641    1554380    1842392  \n    Creatine\n\n135\n0\n135\n1\n850572\n863036\n280966\n\n\n  377778    545055    725328    864268    1005066    1127007    1218109  \n    Asparagine\n\n135\n0\n135\n1\n8943\n8568\n5225\n\n\n  2664    3627    5613    8494    11664    15325    17632  \n    Aspartic_Acid\n\n135\n0\n135\n1\n1773\n1715\n1997\n\n\n  39.96    69.65    153.67    923.68    3253.44    4085.23    5324.57  \n    Adenine\n\n135\n0\n135\n1\n103095\n97434\n68946\n\n\n  12758    35063    58661    97296    132366    178952    209281  \n    Hypoxanthine\n\n134\n1\n134\n1\n936038\n918138\n671574\n\n\n  121502    206919    445774    919651    1366879    1740503    1931342  \n    Anthranilic\n\n116\n19\n116\n1\n736.4\n727.5\n364.7\n\n\n  207.1    316.8    537.4    719.3    953.9    1122.2    1254.7  \n    Glutamine\n\n135\n0\n135\n1\n458006\n439093\n290788\n\n\n  124442    190326    247251    378888    610074    795510    1001633  \n    Lysine\n\n129\n6\n129\n1\n69861\n69889\n75607\n\n\n  744.9    937.6    1678.4    61231.9    126306.9    160549.3    178740.8  \n    Methionine\n\n135\n0\n135\n1\n29887\n28032\n11730\n\n\n  16347    19550    23448    26738    32933    47610    53560  \n    Guanine\n\n110\n25\n110\n1\n22.21\n19.12\n21.56\n\n\n  2.100    3.044    6.374    14.614    30.756    51.083    64.624  \n    Xanthine\n\n131\n4\n131\n1\n41967\n41718\n25829\n\n\n  7433    11655    24411    41070    58730    71539    78269  \n    Allantoin\n\n133\n2\n133\n1\n21337\n21257\n8417\n\n\n  6522    12899    17130    21042    25588    28610    30992  \n    Tryptamine\n\n129\n6\n129\n1\n28.62\n24.79\n25.36\n\n\n  4.105    5.946    10.531    22.130    35.508    57.258    65.890  \n    Phenylalanine\n\n135\n0\n135\n1\n516449\n508093\n166958\n\n\n  263522    349229    438825    498913    587719    708804    785229  \n    3_Methylhistidine\n\n135\n0\n135\n1\n29800\n27832\n29823\n\n\n  810.5    1788.8    6341.4    23229.2    47803.1    61226.2    70634.8  \n    Cotinine\n\n135\n0\n135\n1\n19034\n18915\n12927\n\n\n  2243    4656    9052    18179    28519    34334    37667  \n    Fructose\n\n134\n1\n134\n1\n2471\n2452\n971.3\n\n\n  1117    1457    1950    2460    2924    3518    3812  \n    Theobromine\n\n63\n72\n63\n1\n27.46\n22.49\n26.79\n\n\n  2.196    4.243    9.492    16.884    36.399    71.577    84.793  \n    Tyrosine\n\n135\n0\n135\n1\n24594\n24055\n11224\n\n\n  12336    14112    16597    22589    31604    37578    42225  \n    Mannitol\n\n124\n11\n124\n1\n76.84\n70.37\n63.84\n\n\n  3.253    8.234    33.605    63.437    105.467    155.582    200.262  \n    Caffeine\n\n130\n5\n130\n1\n79.59\n71.97\n69.01\n\n\n  6.41    12.10    31.78    62.95    111.22    145.85    166.13  \n    Acetylcarnitine\n\n135\n0\n135\n1\n3887604\n3851093\n1272483\n\n\n  2406126    2623392    3072928    3737604    4649211    5433679    5872830  \n    Tryptophan\n\n135\n0\n135\n1\n82197\n81686\n29116\n\n\n  45697    52842    62781    84660    100089    112871    122827  \n    Indole_3_Lactic_Acid\n\n127\n8\n127\n1\n43.47\n38.71\n44.44\n\n\n  1.888    2.876    7.343    30.058    66.568    102.035    112.959  \n    Xanthurenic_Acid\n\n115\n20\n115\n1\n81.03\n82.95\n87.55\n\n\n  4.299    5.071    7.771    25.750    156.723    183.876    213.303  \n    5OH_L_Tryptophan\n\n134\n1\n134\n1\n101.7\n100\n40.94\n\n\n  47.50    60.16    80.11    99.30    122.08    150.67    171.81  \n    Thymidine\n\n134\n1\n134\n1\n16919\n17596\n5440\n\n\n  5560    9781    15367    17913    19929    22369    23469  \n    Cytidine\n\n135\n0\n135\n1\n34627\n30424\n33932\n\n\n  8446    9509    10901    15049    53533    77398    116167  \n    Adenosine\n\n133\n2\n133\n1\n539474\n509577\n372788\n\n\n  42119    178147    301811    492637    719130    953744    1113718  \n    Inosine\n\n134\n1\n134\n1\n18941\n18063\n8840\n\n\n  8832    10507    13175    17650    23421    30479    35001  \n    Lactose\n\n123\n12\n123\n1\n44.23\n33.64\n42.9\n\n\n  8.522    9.535    15.714    26.728    59.258    105.604    140.334  \n    Glycolic\n\n88\n47\n88\n1\n12.72\n8.368\n16.61\n\n\n  0.3601    0.6285    1.6980    3.2760    21.9630    41.4577    46.2001  \n    Pyruvic\n\n133\n2\n133\n1\n2086\n2072\n1048\n\n\n  620.8    964.2    1394.3    2092.1    2749.9    3134.6    3656.0  \n    Lactic_Acid\n\n135\n0\n135\n1\n2580\n2591\n1304\n\n\n  590.1    1123.1    1908.5    2550.7    3342.8    4152.8    4502.2  \n    Benzoic_Acid\n\n134\n1\n134\n1\n20.6\n20.76\n7.334\n\n\n  10.20    12.28    17.22    21.21    24.04    29.56    31.51  \n    Homocysteine\n\n104\n31\n104\n1\n11.36\n9.398\n12.06\n\n\n  0.2510    0.5294    3.0005    7.8310    16.2197    30.1079    35.3650  \n    Ribose\n\n135\n0\n135\n1\n58.64\n38.9\n71.37\n\n\n  4.110    5.716    9.588    22.547    78.739    182.974    227.937  \n    Xylitol\n\n113\n22\n113\n1\n4.569\n3.896\n4.647\n\n\n  0.3224    0.4902    1.2120    2.7670    6.4430    11.4452    13.9886  \n    Arabitol\n\n111\n24\n110\n1\n3.359\n2.955\n3.298\n\n\n  0.1960    0.3210    0.9495    2.3630    4.8680    7.6020    9.7850  \n    Ascorbic_Acid\n\n134\n1\n134\n1\n45.19\n44.39\n36.67\n\n\n  1.793    3.345    15.849    45.382    66.610    94.125    102.456  \n    Hippuric_Acid\n\n98\n37\n98\n1\n105.6\n90.96\n145.2\n\n\n  0.2394    0.6285    1.7450    9.0705    198.7158    315.3347    398.7045  \n    Glucose\n\n135\n0\n135\n1\n1790\n1829\n640.5\n\n\n  645.1    988.1    1503.6    1860.6    2151.0    2412.0    2558.7  \n    Mannose\n\n134\n1\n134\n1\n2178\n2290\n1017\n\n\n  375.7    515.2    1773.7    2419.1    2765.3    3160.9    3444.0  \n    Inositol\n\n87\n48\n87\n1\n7.221\n3.821\n9.558\n\n\n  0.2215    0.4726    1.0235    2.5620    7.1655    23.7392    31.3565  \n    Sorbitol\n\n78\n57\n77\n1\n8.037\n3.296\n11.04\n\n\n  0.1477    0.2143    0.7765    2.1340    5.7780    29.2574    32.9332  \n    Uridine\n\n135\n0\n135\n1\n1944\n1954\n914.3\n\n\n  227.1    997.3    1493.6    1950.0    2484.3    2856.8    3327.7  \n    Maltose\n\n110\n25\n110\n1\n6.544\n5.446\n6.76\n\n\n  0.3386    0.7923    1.6010    4.1180    8.7125    15.7619    19.3221  \n  \n  \n  \n\n\n\n\n\n\n\n  \n    \n      Metabolite Data Descriptives\n    \n    \n      4 Categorical Variables of 79 Variables, 135 Observations\n    \n    \n      Variable\n      Label\n      n\n      Missing\n      Distinct\n      Info\n      Mean\n      pMedian\n      Gini‚Äâ|Œî|\n       \n    \n  \n  \n    ID\n\n135\n0\n34\n\n\n\n\n\n\n    Time_Point\nWeek in treatment\n135\n0\n4\n0.938\n1.496\n1.5\n1.263\n\n\n    NutrMod\nNutritional Model: Controls (normal diet), HC (high carbs diet) and  HFHC (high fat and high carb diet)\n135\n0\n3\n\n\n\n\n\n\n    Month\n\n135\n0\n4\n0.938\n1.496\n1.5\n1.263",
    "crumbs": [
      "Sections",
      "Processing & EDA"
    ]
  },
  {
    "objectID": "data_metabolic_syndrome.html#metabolite-data-descriptions-eda",
    "href": "data_metabolic_syndrome.html#metabolite-data-descriptions-eda",
    "title": "Data Description/Processing - Metabolic Syndrome In Rats",
    "section": "",
    "text": "Metabolic syndrome is associated with several metabolites that reflect alterations in glucose, lipid, amino acid, and energy metabolism. Key metabolites include:\n\nLipid Metabolites\n\nTriglycerides (TG): Elevated in metabolic syndrome, indicating impaired fat metabolism. Free fatty acids (FFA): Increased levels contribute to insulin resistance and inflammation. Low-density lipoprotein (LDL) and Very-low-density lipoprotein (VLDL): Higher levels of these ‚Äúbad‚Äù cholesterol types are common. High-density lipoprotein (HDL): Reduced ‚Äúgood‚Äù cholesterol levels are a marker of metabolic syndrome. Ceramides: Bioactive lipids linked to insulin resistance and cardiovascular disease.\n\nGlucose and Energy Metabolites\n\nGlucose: Elevated fasting glucose is a diagnostic marker of metabolic syndrome. Insulin: High levels indicate insulin resistance. Lactate: Increased due to altered glycolysis and mitochondrial dysfunction. Ketone bodies (Œ≤-hydroxybutyrate, acetoacetate): Altered levels indicate disrupted fatty acid oxidation.\n\nAmino Acid Metabolites\n\nBranched-chain amino acids (BCAAs) (Leucine, Isoleucine, Valine): Elevated levels are strongly linked to insulin resistance. Aromatic amino acids (Tyrosine, Phenylalanine): Increased levels are associated with obesity and diabetes risk. Glutamate and Glutamine: Higher glutamate and lower glutamine levels are associated with metabolic dysfunction.\n\nInflammatory and Oxidative Stress Metabolites\n\nC-reactive protein (CRP): A marker of systemic inflammation. Homocysteine: Elevated levels are linked to cardiovascular risk. Oxidized LDL: A marker of oxidative stress and atherosclerosis risk.\n\nGut Microbiome-Derived Metabolites\n\nShort-chain fatty acids (SCFAs) (Butyrate, Acetate, Propionate): Reduced levels may indicate an unhealthy gut microbiome. Trimethylamine-N-oxide (TMAO): Elevated levels are associated with cardiovascular disease risk. These metabolites collectively indicate metabolic dysfunction, insulin resistance, and increased cardiovascular risk. Monitoring and targeting these biomarkers through diet, exercise, and medications can help manage metabolic syndrome.\n‚úÖ Strongly Associated Biomarkers for Metabolic Syndrome:\n\nTrimethylamine N-oxide (TMAO) ‚Äì Elevated levels are linked to cardiovascular disease, insulin resistance, and gut microbiota imbalance.\nCholine ‚Äì Essential for lipid metabolism; imbalances are linked to NAFLD and insulin resistance.\nSerine ‚Äì Low levels are associated with insulin resistance and metabolic dysfunction.\nGlycine ‚Äì Reduced in MetS; involved in antioxidant defense and glucose metabolism.\nAlanine ‚Äì Increased in MetS; involved in gluconeogenesis and insulin resistance.\nIsoleucine ‚Äì Branched-chain amino acid (BCAA) associated with obesity, insulin resistance, and metabolic dysfunction.\nLeucine ‚Äì Elevated levels correlate with MetS, obesity, and T2D.\nCreatinine ‚Äì A marker of muscle metabolism and kidney function, associated with insulin resistance and MetS progression.\nTaurine ‚Äì Linked to lipid metabolism, blood pressure regulation, and oxidative stress.\nBetaine ‚Äì Plays a role in homocysteine metabolism; imbalances can contribute to cardiovascular risk.\nTyrosine ‚Äì Elevated in insulin resistance and metabolic dysfunction.\nPhenylalanine ‚Äì Increased in MetS, linked to impaired glucose metabolism.\nAcetylcarnitine ‚Äì Implicated in fatty acid metabolism dysfunction in MetS.\nFructose ‚Äì High intake contributes to insulin resistance and fatty liver disease.\nGlucose ‚Äì A core biomarker of insulin resistance and diabetes.\nMannose ‚Äì Altered metabolism is linked to insulin resistance.\nLactic Acid ‚Äì Increased in mitochondrial dysfunction and metabolic disorders.\nPyruvic Acid (Pyruvate) ‚Äì Involved in glycolysis; alterations signal metabolic dysfunction.\n\nüü° Moderately Associated Biomarkers (Need Further Validation):\n\nPutrescine & Cadaverine ‚Äì Polyamines linked to gut microbiota and inflammation in MetS.\nSarcosine ‚Äì Related to methylation and lipid metabolism, but its role in MetS is unclear.\nHistamine ‚Äì Involved in inflammatory responses and metabolic homeostasis.\nHypotaurine ‚Äì Precursor to taurine; may help counter oxidative stress in MetS.\nAsparagine ‚Äì Altered levels may reflect amino acid metabolism changes in MetS.\nAspartic Acid ‚Äì May be involved in energy metabolism and oxidative stress.\nMethionine ‚Äì Essential for methylation reactions; altered levels may affect lipid metabolism.\nLysine ‚Äì Essential amino acid; its metabolic disturbances could relate to insulin resistance.\nAnthranilic Acid ‚Äì A metabolite of tryptophan linked to inflammation and gut microbiota.\nIndole-3-Lactic Acid ‚Äì Gut-derived metabolite with possible metabolic and inflammatory implications.\n5-Hydroxy-L-Tryptophan (5OH-L-Tryptophan) ‚Äì A serotonin precursor involved in neuroendocrine and metabolic regulation.\nXanthurenic Acid ‚Äì A tryptophan metabolite associated with insulin resistance and oxidative stress.\nBenzoic Acid ‚Äì Related to gut microbiota metabolism, possibly linked to MetS.\nXanthine & Hypoxanthine ‚Äì Purine metabolism intermediates; increased levels may be linked to oxidative stress and insulin resistance.\n\n‚ùå Less Relevant or Weak Evidence for MetS:\nThese metabolites are less directly linked to metabolic syndrome but may still have indirect roles:\n\nMethylamine, Dimethylamine, Trimethylamine ‚Äì Related to gut metabolism but not primary MetS markers. Monoisoamylamine ‚Äì Limited data on its role in MetS.\nCytosine, Uracil, Thymine, Adenine, Guanine, Cytidine, Thymidine, Adenosine, Inosine, Uridine, Maltose, Ribose, Xylitol, Arabitol ‚Äì These are nucleotides and sugars with limited direct associations to MetS.\nCaffeine ‚Äì May have protective effects against MetS but is not a biomarker.\nCotinine ‚Äì A nicotine metabolite, not directly related to MetS.\nMannitol, Lactose, Ascorbic Acid (Vitamin C) ‚Äì Not considered primary biomarkers for MetS.\n\nüìå Summary:\nStrongest biomarkers: TMAO, Choline, Serine, Glycine, Alanine, BCAAs (Isoleucine, Leucine), Taurine, Betaine, Acetylcarnitine, Glucose, Lactic Acid, Fructose.\nModerate biomarkers: Polyamines (Putrescine, Cadaverine), Tryptophan metabolites, Histamine, Hypotaurine.\nLess relevant metabolites: Nucleotides, sugar alcohols, caffeine.\n\n\n\n\nüìå Summary: Best Predictors of TMAO\nüî• Strongest Predictors: Choline, Betaine, Carnitine (Acetylcarnitine), Trimethylamine, Dimethylamine, Methylamine\nüü° Moderate Predictors: Serine, Methionine, Glycine, Taurine, Creatinine, Histamine, Hypotaurine\n‚ö†Ô∏è Weaker Indirect Predictors: Fructose, Glucose, Lactic Acid, Pyruvic Acid, Xanthurenic Acid, Putrescine, Cadaverine\n\n\n\nüìå Summary: Best Predictors of Choline\nüî• Strongest Predictors: Betaine, Serine, Methionine, Glycine, Acetylcarnitine\nüü° Moderate Predictors: Trimethylamine, Dimethylamine, Methylamine, Taurine, Histamine, Creatinine\n‚ö†Ô∏è Weaker Indirect Predictors: Fructose, Glucose, Lactic Acid, Pyruvic Acid, Xanthurenic Acid, Putrescine, Cadaverine\n\n\n\nüìå Summary: Best Predictors of Serine\nüî• Strongest Predictors: Glycine, Methionine, Asparagine, Aspartic Acid, Glutamine, Pyruvic Acid\nüü° Moderate Predictors: Choline, Betaine, Taurine, Histamine, Lactic Acid\n‚ö†Ô∏è Weaker Indirect Predictors: Fructose, Glucose, Xanthurenic Acid, Putrescine, Cadaverine, Creatinine\n\n\n\nüìå Summary: Best Predictors of Glycine\nüî• Strongest Predictors: Serine, Methionine, Choline, Betaine, Glutamine, Aspartic Acid\nüü° Moderate Predictors: Taurine, Histamine, Acetylcarnitine, Creatinine, Lactic Acid\n‚ö†Ô∏è Weaker Indirect Predictors: Fructose, Glucose, Xanthurenic Acid, Putrescine, Cadaverine, Phenylalanine\n\n\n\nüìå Summary: Best Predictors of Alanine\nüî• Strongest Predictors: Pyruvic Acid, Aspartic Acid, Glutamine, Glutamate, Lactic Acid, Asparagine\nüü° Moderate Predictors: Serine, Glycine, Methionine, Creatinine, Glucose, Fructose\n‚ö†Ô∏è Weaker Indirect Predictors: Xanthurenic Acid, Putrescine, Cadaverine, Phenylalanine, Taurine\n\n\n\nüìå Summary: Best Predictors of Isoleucine\nüî• Strongest Predictors: Leucine, Valine, Aspartic Acid, Glutamine, Pyruvic Acid\nüü° Moderate Predictors: Alanine, Serine, Methionine, Creatinine, Lactic Acid, Glucose\n‚ö†Ô∏è Weaker Indirect Predictors: Histamine, Taurine, Xanthurenic Acid, Putrescine, Fructose\n\n\n\nüìå Summary: Best Predictors of Leucine\nüî• Strongest Predictors: Isoleucine, Valine, Aspartic Acid, Glutamine, Pyruvic Acid\nüü° Moderate Predictors: Alanine, Serine, Methionine, Creatinine, Lactic Acid, Glucose\n‚ö†Ô∏è Weaker Indirect Predictors: Histamine, Taurine, Xanthurenic Acid, Putrescine, Fructose\n\n\n\nüìå Summary: Best Predictors of Creatinine\nüî• Strongest Predictors: Creatine, Isoleucine, Leucine, Alanine, Glutamine, Glutamate\nüü° Moderate Predictors: Valine, Methionine, Aspartic Acid, Pyruvic Acid, Lactic Acid, Glucose, Fructose\n‚ö†Ô∏è Weaker Indirect Predictors: Histamine, Taurine, Xanthurenic Acid, Putrescine, Mannose, Ribose\n\n\n\nüìå Summary: Best Predictors of Taurine\nüî• Strongest Predictors: Methionine, Hypotaurine, Glutamine, Glutamate, Aspartic Acid\nüü° Moderate Predictors: Serine, Alanine, Creatinine, Glucose, Fructose, Lactic Acid, Pyruvic Acid\n‚ö†Ô∏è Weaker Indirect Predictors: Histamine, Xanthurenic Acid, Putrescine, Mannose, Ribose\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\nFigure¬†4: Correlation plot of metabolites considering all time points and nutrition models. In general the correlations are positive and high, which might be expected as the majority of data points correspond to one of the two nutrition models i.e.¬†metabolite concentrations are overall affected by the diet treatment.\n\n\n\n\n\n\n\n\nNote that p-values shown below are FDR adjusted at \\(a = 0.2\\) for all nutritional model comparisons i.e.¬†FDR_algc-adj, but not for any metabolite data (see modeling page for this).\n\n\nNotable cases: [[plot_number]] Metabolite:\n\n[[11]] Choline\n[[12]] g_aminobutyric\n[[14]] Hypotaurine\n[[18]] Creatinine\n[[21]] Norvaline_Valine\n[[23]] Taurine\n[[28]] Leucine\n[[33]] Hypoxanthine\n[[42]] Phenylalanine\n[[51]] Tryptophan\n[[55]] Thymidine\n\n\n\n[[1]]\n\n\n\n\n\n\n\n\n\n\n[[2]]\n\n\n\n\n\n\n\n\n\n\n[[3]]\n\n\n\n\n\n\n\n\n\n\n[[4]]\n\n\n\n\n\n\n\n\n\n\n[[5]]\n\n\n\n\n\n\n\n\n\n\n[[6]]\n\n\n\n\n\n\n\n\n\n\n[[7]]\n\n\n\n\n\n\n\n\n\n\n[[8]]\n\n\n\n\n\n\n\n\n\n\n[[9]]\n\n\n\n\n\n\n\n\n\n\n[[10]]\n\n\n\n\n\n\n\n\n\n\n[[11]]\n\n\n\n\n\n\n\n\n\n\n[[12]]\n\n\n\n\n\n\n\n\n\n\n[[13]]\n\n\n\n\n\n\n\n\n\n\n[[14]]\n\n\n\n\n\n\n\n\n\n\n[[15]]\n\n\n\n\n\n\n\n\n\n\n[[16]]\n\n\n\n\n\n\n\n\n\n\n[[17]]\n\n\n\n\n\n\n\n\n\n\n[[18]]\n\n\n\n\n\n\n\n\n\n\n[[19]]\n\n\n\n\n\n\n\n\n\n\n[[20]]\n\n\n\n\n\n\n\n\n\n\n[[21]]\n\n\n\n\n\n\n\n\n\n\n[[22]]\n\n\n\n\n\n\n\n\n\n\n[[23]]\n\n\n\n\n\n\n\n\n\n\n[[24]]\n\n\n\n\n\n\n\n\n\n\n[[25]]\n\n\n\n\n\n\n\n\n\n\n[[26]]\n\n\n\n\n\n\n\n\n\n\n[[27]]\n\n\n\n\n\n\n\n\n\n\n[[28]]\n\n\n\n\n\n\n\n\n\n\n[[29]]\n\n\n\n\n\n\n\n\n\n\n[[30]]\n\n\n\n\n\n\n\n\n\n\n[[31]]\n\n\n\n\n\n\n\n\n\n\n[[32]]\n\n\n\n\n\n\n\n\n\n\n[[33]]\n\n\n\n\n\n\n\n\n\n\n[[34]]\n\n\n\n\n\n\n\n\n\n\n[[35]]\n\n\n\n\n\n\n\n\n\n\n[[36]]\n\n\n\n\n\n\n\n\n\n\n[[37]]\n\n\n\n\n\n\n\n\n\n\n[[38]]\n\n\n\n\n\n\n\n\n\n\n[[39]]\n\n\n\n\n\n\n\n\n\n\n[[40]]\n\n\n\n\n\n\n\n\n\n\n[[41]]\n\n\n\n\n\n\n\n\n\n\n[[42]]\n\n\n\n\n\n\n\n\n\n\n[[43]]\n\n\n\n\n\n\n\n\n\n\n[[44]]\n\n\n\n\n\n\n\n\n\n\n[[45]]\n\n\n\n\n\n\n\n\n\n\n[[46]]\n\n\n\n\n\n\n\n\n\n\n[[47]]\n\n\n\n\n\n\n\n\n\n\n[[48]]\n\n\n\n\n\n\n\n\n\n\n[[49]]\n\n\n\n\n\n\n\n\n\n\n[[50]]\n\n\n\n\n\n\n\n\n\n\n[[51]]\n\n\n\n\n\n\n\n\n\n\n[[52]]\n\n\n\n\n\n\n\n\n\n\n[[53]]\n\n\n\n\n\n\n\n\n\n\n[[54]]\n\n\n\n\n\n\n\n\n\n\n[[55]]\n\n\n\n\n\n\n\n\n\n\n[[56]]\n\n\n\n\n\n\n\n\n\n\n[[57]]\n\n\n\n\n\n\n\n\n\n\n[[58]]\n\n\n\n\n\n\n\n\n\n\n[[59]]\n\n\n\n\n\n\n\n\n\n\n[[60]]\n\n\n\n\n\n\n\n\n\n\n[[61]]\n\n\n\n\n\n\n\n\n\n\n[[62]]\n\n\n\n\n\n\n\n\n\n\n[[63]]\n\n\n\n\n\n\n\n\n\n\n[[64]]\n\n\n\n\n\n\n\n\n\n\n[[65]]\n\n\n\n\n\n\n\n\n\n\n[[66]]\n\n\n\n\n\n\n\n\n\n\n[[67]]\n\n\n\n\n\n\n\n\n\n\n[[68]]\n\n\n\n\n\n\n\n\n\n\n[[69]]\n\n\n\n\n\n\n\n\n\n\n[[70]]\n\n\n\n\n\n\n\n\n\n\n[[71]]\n\n\n\n\n\n\n\n\n\n\n[[72]]\n\n\n\n\n\n\n\n\n\n\n[[73]]\n\n\n\n\n\n\n\n\n\n\n[[74]]\n\n\n\n\n\n\n\n\n\n\n[[75]]",
    "crumbs": [
      "Sections",
      "Processing & EDA"
    ]
  },
  {
    "objectID": "data_metabolic_syndrome.html#clinical-data-post-mortem",
    "href": "data_metabolic_syndrome.html#clinical-data-post-mortem",
    "title": "Data Description/Processing - Metabolic Syndrome In Rats",
    "section": "",
    "text": "ContinuousCategorical\n\n\n\n\n\n  \n    \n    \n    \n    \n    \n    \n    \n    \n    \n    \n    \n  \n  \n    \n      Clinical Data (post-mortem) Descriptives\n    \n    \n      22 Continous Variables of 25 Variables, 34 Observations\n    \n    \n      Variable\n      Label\n      n\n      Missing\n      Distinct\n      Info\n      Mean\n      pMedian\n      Gini‚Äâ|Œî|\n       \n      Quantiles .05  .10  .25  .50  .75  .90  .95 \n    \n  \n  \n    Glucose\n\n34\n0\n27\n0.999\n149.7\n146.5\n25.54\n\n\n  118.6    131.3    140.0    146.0    153.8    181.3    202.1  \n    Glucose_œÑŒ±ŒπŒΩŒØŒµœÇ\n\n34\n0\n23\n0.997\n136.9\n137.5\n13.55\n\n\n  114.2    125.3    131.0    139.0    143.0    149.7    154.7  \n    Weight\n\n34\n0\n30\n0.999\n468.4\n463.5\n48.08\n\n\n  414.0    422.3    435.0    458.5    487.2    515.4    549.3  \n    BUN\n\n34\n0\n18\n0.996\n35.56\n31.5\n13.05\n\n\n  25.65    26.00    28.00    31.00    34.75    38.40    42.75  \n    Uric_Œëcid\n\n34\n0\n13\n0.988\n1.318\n1.25\n0.4364\n\n\n  0.800    0.860    1.025    1.250    1.475    1.800    2.105  \n    Creatinine\n\n34\n0\n14\n0.985\n0.4924\n0.435\n0.1554\n\n\n  0.380    0.393    0.410    0.425    0.460    0.490    0.497  \n    Tchol\n\n34\n0\n30\n0.999\n126.1\n124.5\n35.94\n\n\n  86.25    91.30    97.75    125.00    148.75    160.80    180.15  \n    Triglycerides\n\n32\n2\n30\n1.000\n267\n243.8\n174.9\n\n\n  90.2    115.7    148.0    231.0    320.0    496.1    597.2  \n    HDL\n\n34\n0\n23\n0.998\n36.94\n36.5\n10.47\n\n\n  24.30    27.30    30.25    35.00    41.75    48.00    54.40  \n    LDL\n\n34\n0\n14\n0.987\n9.147\n9\n3.995\n\n\n  5.00    5.30    7.00    8.00    11.75    14.70    16.00  \n    VLDL\n\n34\n0\n28\n0.999\n52.97\n48.5\n34.5\n\n\n  18.25    23.30    29.25    46.00    65.25    95.00    118.75  \n    TGL_HDL_ratio\n\n32\n2\n31\n1.000\n7.588\n6.37\n5.321\n\n\n  2.776    3.390    4.330    5.600    8.508    12.689    15.953  \n    Atherogenic_Index\n\n32\n2\n27\n0.999\n0.7975\n0.78\n0.2801\n\n\n  0.4415    0.5310    0.6375    0.7500    0.9275    1.1000    1.2015  \n    AST\n\n34\n0\n31\n1.000\n116.1\n107.5\n48.4\n\n\n  72.30    74.30    87.25    102.00    125.75    157.70    189.95  \n    ALT\n\n34\n0\n25\n0.998\n36.59\n36.5\n12.15\n\n\n  23.3    24.0    27.0    37.0    43.0    49.7    52.7  \n    ALP\n\n34\n0\n30\n0.999\n130.9\n129\n41.33\n\n\n  90.65    91.30    100.50    121.50    159.00    185.40    188.10  \n    ALB\n\n34\n0\n11\n0.975\n3.324\n3.35\n0.2909\n\n\n  2.965    3.030    3.200    3.350    3.475    3.670    3.700  \n    FERRITIN\n\n34\n0\n34\n1.000\n7.151\n6.97\n2.973\n\n\n  3.903    4.061    5.380    6.610    8.705    10.425    11.817  \n    LDH\n\n34\n0\n31\n1.000\n567.9\n537\n210.7\n\n\n  336.6    369.3    450.8    520.0    627.8    872.5    993.8  \n    AMYLASE\n\n34\n0\n34\n1.000\n2119\n2136\n373.4\n\n\n  1578    1719    1916    2176    2358    2496    2564  \n    Mg\n\n34\n0\n29\n0.999\n2.833\n2.77\n0.3814\n\n\n  2.497    2.520    2.590    2.755    2.962    3.074    3.131  \n    D3\n\n34\n0\n33\n1.000\n41.5\n41.75\n6.52\n\n\n  31.97    33.26    38.75    41.85    45.88    48.94    49.24  \n  \n  \n  \n\n\n\n\n\n\n\n  \n    \n      Clinical Data (post-mortem) Descriptives\n    \n    \n      3 Categorical Variables of 25 Variables, 34 Observations\n    \n    \n      Variable\n      Label\n      n\n      Missing\n      Distinct\n      Info\n      Mean\n      pMedian\n      Gini‚Äâ|Œî|\n       \n    \n  \n  \n    ID\n\n34\n0\n34\n\n\n\n\n\n\n    NutrMod\n\n34\n0\n3\n0.876\n2.147\n2\n0.8574\n\n\n    Na\n\n34\n0\n9\n0.953\n145.3\n145\n2.005\n\n\n  \n  \n  \n\n\n\n\n\n\n\nNote that p-values shown below are FDR adjusted at \\(a = 0.2\\) for all nutritional model comparisons i.e.¬†FDR_algc-adj, but not for any metabolite data (see modeling page for this).\nNotable cases: [[plot_number]] Clinical Metric:\n\n[[7]] Tchol\n[[9]] HDL\n[[10]] LDL\n[[11]] VLDL\n[[15]] ALT\n[[16]] ALP\n[[20]] Amylase\n\n\n\n[[1]]\n\n\n\n\n\n\n\n\n\n\n[[2]]\n\n\n\n\n\n\n\n\n\n\n[[3]]\n\n\n\n\n\n\n\n\n\n\n[[4]]\n\n\n\n\n\n\n\n\n\n\n[[5]]\n\n\n\n\n\n\n\n\n\n\n[[6]]\n\n\n\n\n\n\n\n\n\n\n[[7]]\n\n\n\n\n\n\n\n\n\n\n[[8]]\n\n\n\n\n\n\n\n\n\n\n[[9]]\n\n\n\n\n\n\n\n\n\n\n[[10]]\n\n\n\n\n\n\n\n\n\n\n[[11]]\n\n\n\n\n\n\n\n\n\n\n[[12]]\n\n\n\n\n\n\n\n\n\n\n[[13]]\n\n\n\n\n\n\n\n\n\n\n[[14]]\n\n\n\n\n\n\n\n\n\n\n[[15]]\n\n\n\n\n\n\n\n\n\n\n[[16]]\n\n\n\n\n\n\n\n\n\n\n[[17]]\n\n\n\n\n\n\n\n\n\n\n[[18]]\n\n\n\n\n\n\n\n\n\n\n[[19]]\n\n\n\n\n\n\n\n\n\n\n[[20]]\n\n\n\n\n\n\n\n\n\n\n[[21]]\n\n\n\n\n\n\n\n\n\n\n[[22]]\n\n\n\n\n\n\n\n\n\n\n[[23]]",
    "crumbs": [
      "Sections",
      "Processing & EDA"
    ]
  },
  {
    "objectID": "data_metabolic_syndrome.html#t2d-data",
    "href": "data_metabolic_syndrome.html#t2d-data",
    "title": "Data Description/Processing - Metabolic Syndrome In Rats",
    "section": "",
    "text": "Note that p-values shown below are FDR adjusted at \\(a = 0.05\\) for all nutritional model comparisons but separately for each metabolite.\n\n\n[[1]]\n\n\n\n\n\n\n\n\n\n\n[[2]]\n\n\n\n\n\n\n\n\n\n\n[[3]]\n\n\n\n\n\n\n\n\n\n\n[[4]]\n\n\n\n\n\n\n\n\n\n\n[[5]]\n\n\n\n\n\n\n\n\n\n\n[[6]]\n\n\n\n\n\n\n\n\n\n\n[[7]]\n\n\n\n\n\n\n\n\n\n\n[[8]]\n\n\n\n\n\n\n\n\n\n\n[[9]]\n\n\n\n\n\n\n\n\n\n\n[[10]]\n\n\n\n\n\n\n\n\n\n\n[[11]]\n\n\n\n\n\n\n\n\n\n\n[[12]]",
    "crumbs": [
      "Sections",
      "Processing & EDA"
    ]
  },
  {
    "objectID": "data_metabolic_syndrome.html#post-mortem-lipids",
    "href": "data_metabolic_syndrome.html#post-mortem-lipids",
    "title": "Data Description/Processing - Metabolic Syndrome In Rats",
    "section": "",
    "text": "See the Modeling page for both a univariate and multivariate analysis on lipids collected at post-mortem stage, as well as their differences amongst the nutritional models.",
    "crumbs": [
      "Sections",
      "Processing & EDA"
    ]
  },
  {
    "objectID": "modeling_metabolic_syndrome.html",
    "href": "modeling_metabolic_syndrome.html",
    "title": "Modeling & Assessing Metabolic Syndrome In Rats (Metabolite Added Value)",
    "section": "",
    "text": "Analysis‚Äô focus is to examine the effects of nutritional models (i.e.¬†plans) either directly on clinical measurements that might be associated with the metabolic syndrome or indirectly on metabolites that could have a potential association with the metabolic syndrome.",
    "crumbs": [
      "Sections",
      "Modeling"
    ]
  },
  {
    "objectID": "modeling_metabolic_syndrome.html#dimethylamine---surrogate-of-bun",
    "href": "modeling_metabolic_syndrome.html#dimethylamine---surrogate-of-bun",
    "title": "Modeling & Assessing Metabolic Syndrome In Rats (Metabolite Added Value)",
    "section": "Dimethylamine - Surrogate Of BUN",
    "text": "Dimethylamine - Surrogate Of BUN\nThe BUN clinical measurement stands for Blood Urea Nitrogen.\nIt is a common blood test that measures the amount of urea nitrogen in blood.\nUrea nitrogen is a waste product that forms in the liver when the body breaks down proteins (amino acids). It travels in the bloodstream to the kidneys, which normally filter it out and remove it from the body in the urine.\nThe primary use of the BUN test is to evaluate kidney function.\n\nIf the kidneys are not working properly, they may not be able to filter urea nitrogen effectively, causing the BUN level in the blood to rise above the normal range.\nThe test is often ordered as part of a Comprehensive Metabolic Panel (CMP) or Basic Metabolic Panel (BMP).\nIt is frequently compared with the level of creatinine (another waste product) to calculate the BUN-to-Creatinine ratio, which is a more reliable indicator of kidney health and can help diagnose the cause of an abnormal result (e.g., dehydration, heart failure, or direct kidney damage).\n\nHigh BUN Levels\nA higher-than-normal BUN level (azotemia) can suggest:\n\nKidney injury or disease (the most common concern).\nDehydration (low blood flow to the kidneys).\nCongestive heart failure or recent heart attack (also causing low blood flow to the kidneys).\nUrinary tract obstruction.\nA high-protein diet.\nGastrointestinal bleeding.\n\nLow BUN Levels\nA lower-than-normal BUN level is less common but can be associated with:\n\nSevere liver disease (since the liver is where urea is formed).\nMalnutrition or a diet very low in protein.\nOverhydration (drinking too much fluid).\n\nNormal BUN levels generally range between \\(\\text{6}\\) and \\(\\text{24 mg/dL}\\) (milligrams per deciliter), but this can vary based on the lab and ones age and sex.\n\n\n[1] \"Lactose, Ascorbic_Acid, Putrescine, Trimethylamine_n_oxide, Ribose, Trimethylamine, Arabitol, Allantoin, Indole_3_Lactic_Acid, Creatinine\"\n\n\n\n\n\n     ### Summary of continuous variables ###\n\nNutrMod: Overall\n                n miss p.miss mean  sd median p25  p75 min  max  skew kurt\nDimethylamine0 34    0      0  815 549    984 109 1213   1 1720 -0.31 -1.2\n------------------------------------------------------------------------------------------ \nNutrMod: C\n               n miss p.miss mean  sd median p25  p75 min  max  skew kurt\nDimethylamine0 8    0      0  620 469    680 149 1030  40 1179 -0.15 -1.9\n------------------------------------------------------------------------------------------ \nNutrMod: HC\n                n miss p.miss mean  sd median  p25  p75 min  max skew kurt\nDimethylamine0 13    0      0 1133 546   1305 1030 1439   1 1720 -1.4  1.4\n------------------------------------------------------------------------------------------ \nNutrMod: HFHC\n                n miss p.miss mean  sd median p25 p75 min  max  skew kurt\nDimethylamine0 13    0      0  618 476    863  67 972  38 1224 -0.31 -1.9\n\np-values\n                  pNormal pNonNormal\nDimethylamine0 0.02413538 0.01351516\n\nStandardize mean differences\n                average   1 vs 2      1 vs 3   2 vs 3\nDimethylamine0 0.673444 1.008563 0.004941165 1.006828\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\nOverall\nC\nHC\nHFHC\np\ntest\nSMD\n\n\n\n\nn\n34\n8\n13\n13\n\n\n\n\n\nDimethylamine0 (median [IQR])\n983.81 [109.47, 1,212.88]\n680.38 [148.51, 1,030.49]\n1,304.85 [1,030.29, 1,439.43]\n862.54 [67.48, 972.41]\n0.014\nnonnorm\n0.673\n\n\n\n\n\n¬†\n\n\n\n\n\n\n\n\n\n\n\n(a) Dimethylamine at Month 0 : Baseline\n\n\n\n\n\n\n\n\n\n\n\n(b) Dimethylamine at Months 1-3 : Treatment\n\n\n\n\n\n\n\nFigure¬†1: Proportion of nutritional model instances per metabolite concentration quantile (denoted by the average value of concentrations within each quantile).\n\n\n\n¬†\n\n\n\n\n\n\n\n\n\n\n\n(a) Nutritional Model Odds Ratio on Dimethylamine. HC vs C difference\n\n\n\n\n\n\n\n\n\n\n\n\n\n(b) Nutritional Model Odds Ratio on Dimethylamine. HFHC vs C difference\n\n\n\n\n\n\n\n\n\n\n\n\n\n(c) Nutritional Model Odds Ratio on Dimethylamine. HFHC vs HC difference\n\n\n\n\n\n\n\nFigure¬†2: Average Treatment Effects (ATE)\n\n\n\n¬†\n\n\n\n\n\n\n\n\nFigure¬†3: Dimethylamine nutritional model differences from baseline at t0 (trends)\n\n\n\n\n\n¬†\n\n\n\n\n\n\n\n\nFigure¬†4: Dimethylamine nutritional model differences based on raw data. Dashed horizontal line corresponds to the adjustment value of Dimethylamine at time 0.\n\n\n\n\n\n¬†\n\n\n\n\n\n\n\n\nFigure¬†5: Dimethylamine nutritional model differences from baseline at t0 (split view). Points denote median concentrations and lines denote the corresponding central 80% likelihood intervals.\n\n\n\n\n\n¬†\n\n\n\n\n\n\n\n\n\n\n\n(a) Dimethylamine nutritional model differences versus Dimethylamine at time 0 (trends) using raw data.\n\n\n\n\n\n\n\n\n\n\n\n(b) Dimethylamine nutritional model differences versus Dimethylamine at time 0 (trends) using model adjustment.\n\n\n\n\n\n\n\nFigure¬†6: Effect of adjusting to baseline metabolite value at time 0. Without adjustment, graph (a), the differences of the nutritional models depend on the baseline value. With adjustment, graph (b), the differences of the nutritional models do not depend on the baseline value i.e.¬†trend lines are almost parallel to each other.",
    "crumbs": [
      "Sections",
      "Modeling"
    ]
  },
  {
    "objectID": "modeling_metabolic_syndrome.html#creatinine---surrogate-of-creatinine",
    "href": "modeling_metabolic_syndrome.html#creatinine---surrogate-of-creatinine",
    "title": "Modeling & Assessing Metabolic Syndrome In Rats (Metabolite Added Value)",
    "section": "Creatinine - Surrogate Of Creatinine",
    "text": "Creatinine - Surrogate Of Creatinine\n\n\n[1] \"Arabitol, Allantoin, Trimethylamine, Indole_3_Lactic_Acid, Ribose, Ascorbic_Acid, Lactose, Trimethylamine_n_oxide, 3_Methylhistidine, Putrescine, Dimethylamine\"\n\n\n\n\n\n     ### Summary of continuous variables ###\n\nNutrMod: Overall\n             n miss p.miss   mean    sd median    p25    p75    min    max skew  kurt\nCreatinine0 34    0      0 416780 95499  4e+05 330474 474059 262064 614765 0.42 -0.79\n------------------------------------------------------------------------------------------ \nNutrMod: C\n            n miss p.miss   mean    sd median    p25    p75    min    max skew kurt\nCreatinine0 8    0      0 528211 99995 551884 534786 578055 294854 614765 -2.2  5.5\n------------------------------------------------------------------------------------------ \nNutrMod: HC\n             n miss p.miss   mean    sd median    p25    p75    min    max skew  kurt\nCreatinine0 13    0      0 388394 50979 385406 351877 408273 321035 479180 0.57 -0.39\n------------------------------------------------------------------------------------------ \nNutrMod: HFHC\n             n miss p.miss   mean    sd median    p25    p75    min    max   skew kurt\nCreatinine0 13    0      0 376592 75818 360635 313245 455319 262064 469673 -0.028 -1.8\n\np-values\n                 pNormal  pNonNormal\nCreatinine0 0.0001449719 0.004535012\n\nStandardize mean differences\n             average   1 vs 2   1 vs 3    2 vs 3\nCreatinine0 1.217686 1.761674 1.708695 0.1826875\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\nOverall\nC\nHC\nHFHC\np\ntest\nSMD\n\n\n\n\nn\n34\n8\n13\n13\n\n\n\n\n\nCreatinine0 (median [IQR])\n4e+05 [330,474.23, 474,059.04]\n551,883.75 [534,785.60, 578,054.53]\n385,405.66 [351,877.47, 408,273.16]\n360,635.09 [313,245.34, 455,319.12]\n0.005\nnonnorm\n1.218\n\n\n\n\n\n¬†\n\n\n\n\n\n\n\n\n\n\n\n(a) Creatinine at Month 0 : Baseline\n\n\n\n\n\n\n\n\n\n\n\n(b) Creatinine at Months 1-3 : Treatment\n\n\n\n\n\n\n\nFigure¬†7: Proportion of nutritional model instances per metabolite concentration quantile (denoted by the average value of concentrations within each quantile).\n\n\n\n¬†\n\n\n\n\n\n\n\n\n\n\n\n(a) Nutritional Model Odds Ratio on Creatinine. HC vs C difference\n\n\n\n\n\n\n\n\n\n\n\n\n\n(b) Nutritional Model Odds Ratio on Creatinine. HFHC vs C difference\n\n\n\n\n\n\n\n\n\n\n\n\n\n(c) Nutritional Model Odds Ratio on Creatinine. HFHC vs HC difference\n\n\n\n\n\n\n\nFigure¬†8: Average Treatment Effects (ATE)\n\n\n\n¬†\n\n\n\n\n\n\n\n\nFigure¬†9: Creatinine nutritional model differences from baseline at t0 (trends)\n\n\n\n\n\n¬†\n\n\n\n\n\n\n\n\nFigure¬†10: Creatinine nutritional model differences based on raw data. Dashed horizontal line corresponds to the adjustment value of Creatinine at time 0.\n\n\n\n\n\n¬†\n\n\n\n\n\n\n\n\nFigure¬†11: Creatinine nutritional model differences from baseline at t0 (split view). Points denote median concentrations and lines denote the corresponding central 80% likelihood intervals.\n\n\n\n\n\n¬†\n\n\n\n\n\n\n\n\n\n\n\n(a) Creatinine nutritional model differences versus Creatinine at time 0 (trends) using raw data.\n\n\n\n\n\n\n\n\n\n\n\n(b) Creatinine nutritional model differences versus Creatinine at time 0 (trends) using model adjustment.\n\n\n\n\n\n\n\nFigure¬†12: Effect of adjusting to baseline metabolite value at time 0. Without adjustment, graph (a), the differences of the nutritional models depend on the baseline value. With adjustment, graph (b), the differences of the nutritional models do not depend on the baseline value i.e.¬†trend lines are almost parallel to each other.",
    "crumbs": [
      "Sections",
      "Modeling"
    ]
  },
  {
    "objectID": "modeling_metabolic_syndrome.html#lactic-acid---surrogate-of-na",
    "href": "modeling_metabolic_syndrome.html#lactic-acid---surrogate-of-na",
    "title": "Modeling & Assessing Metabolic Syndrome In Rats (Metabolite Added Value)",
    "section": "Lactic Acid - Surrogate Of Na",
    "text": "Lactic Acid - Surrogate Of Na\n\n\n[1] \"Thymidine\"\n\n\n\n\n\n     ### Summary of continuous variables ###\n\nNutrMod: Overall\n              n miss p.miss mean  sd median  p25  p75  min  max skew kurt\nLactic_Acid0 34    0      0 2488 827   2211 1930 2942 1275 4483  1.1 0.42\n------------------------------------------------------------------------------------------ \nNutrMod: C\n             n miss p.miss mean  sd median  p25  p75  min  max skew kurt\nLactic_Acid0 8    0      0 2091 350   2048 1908 2250 1540 2729 0.42  1.1\n------------------------------------------------------------------------------------------ \nNutrMod: HC\n              n miss p.miss mean  sd median  p25  p75  min  max skew  kurt\nLactic_Acid0 13    0      0 2967 849   2890 2452 3350 1985 4483 0.68 -0.72\n------------------------------------------------------------------------------------------ \nNutrMod: HFHC\n              n miss p.miss mean  sd median  p25  p75  min  max skew kurt\nLactic_Acid0 13    0      0 2253 821   1959 1857 2450 1275 4232  1.4  1.6\n\np-values\n                pNormal pNonNormal\nLactic_Acid0 0.02130556  0.0125301\n\nStandardize mean differences\n               average   1 vs 2    1 vs 3    2 vs 3\nLactic_Acid0 0.8198847 1.348614 0.2560398 0.8550005\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\nOverall\nC\nHC\nHFHC\np\ntest\nSMD\n\n\n\n\nn\n34\n8\n13\n13\n\n\n\n\n\nLactic_Acid0 (median [IQR])\n2,210.92 [1,930.23, 2,941.61]\n2,048.40 [1,908.06, 2,250.37]\n2,890.13 [2,452.19, 3,350.35]\n1,959.41 [1,857.08, 2,449.71]\n0.013\nnonnorm\n0.820\n\n\n\n\n\n¬†\n\n\n\n\n\n\n\n\n\n\n\n(a) Lactic_Acid at Month 0 : Baseline\n\n\n\n\n\n\n\n\n\n\n\n(b) Lactic_Acid at Months 1-3 : Treatment\n\n\n\n\n\n\n\nFigure¬†13: Proportion of nutritional model instances per metabolite concentration quantile (denoted by the average value of concentrations within each quantile).\n\n\n\n¬†\n\n\n\n\n\n\n\n\n\n\n\n(a) Nutritional Model Odds Ratio on Lactic_Acid. HC vs C difference\n\n\n\n\n\n\n\n\n\n\n\n\n\n(b) Nutritional Model Odds Ratio on Lactic_Acid. HFHC vs C difference\n\n\n\n\n\n\n\n\n\n\n\n\n\n(c) Nutritional Model Odds Ratio on Lactic_Acid. HFHC vs HC difference\n\n\n\n\n\n\n\nFigure¬†14: Average Treatment Effects (ATE)\n\n\n\n¬†\n\n\n\n\n\n\n\n\nFigure¬†15: Lactic_Acid nutritional model differences from baseline at t0 (trends)\n\n\n\n\n\n¬†\n\n\n\n\n\n\n\n\nFigure¬†16: Lactic_Acid nutritional model differences based on raw data. Dashed horizontal line corresponds to the adjustment value of Lactic_Acid at time 0.\n\n\n\n\n\n¬†\n\n\n\n\n\n\n\n\nFigure¬†17: Lactic_Acid nutritional model differences from baseline at t0 (split view). Points denote median concentrations and lines denote the corresponding central 80% likelihood intervals.\n\n\n\n\n\n¬†\n\n\n\n\n\n\n\n\n\n\n\n(a) Lactic_Acid nutritional model differences versus Lactic_Acid at time 0 (trends) using raw data.\n\n\n\n\n\n\n\n\n\n\n\n(b) Lactic_Acid nutritional model differences versus Lactic_Acid at time 0 (trends) using model adjustment.\n\n\n\n\n\n\n\nFigure¬†18: Effect of adjusting to baseline metabolite value at time 0. Without adjustment, graph (a), the differences of the nutritional models depend on the baseline value. With adjustment, graph (b), the differences of the nutritional models do not depend on the baseline value i.e.¬†trend lines are almost parallel to each other.",
    "crumbs": [
      "Sections",
      "Modeling"
    ]
  },
  {
    "objectID": "modeling_metabolic_syndrome.html#benzoic-acid---surrogate-of-tgl-to-hdl-ratio",
    "href": "modeling_metabolic_syndrome.html#benzoic-acid---surrogate-of-tgl-to-hdl-ratio",
    "title": "Modeling & Assessing Metabolic Syndrome In Rats (Metabolite Added Value)",
    "section": "Benzoic Acid - Surrogate Of TGL to HDL Ratio",
    "text": "Benzoic Acid - Surrogate Of TGL to HDL Ratio\n\n\n[1] \"Maltose, Fructose, Cytidine, Creatine, Isoleucine, Phenylalanine, Tryptophan, Acetylcarnitine\"\n\n\n\n\n\n     ### Summary of continuous variables ###\n\nNutrMod: Overall\n               n miss p.miss mean  sd median p25 p75 min max  skew  kurt\nBenzoic_Acid0 34    0      0   19 3.6     19  16  22  12  26 -0.28 -0.76\n------------------------------------------------------------------------------------------ \nNutrMod: C\n              n miss p.miss mean  sd median p25 p75 min max  skew kurt\nBenzoic_Acid0 8    0      0   19 4.1     19  16  22  12  23 -0.26   -1\n------------------------------------------------------------------------------------------ \nNutrMod: HC\n               n miss p.miss mean  sd median p25 p75 min max  skew kurt\nBenzoic_Acid0 13    0      0   19 4.2     20  15  22  13  26 -0.24   -1\n------------------------------------------------------------------------------------------ \nNutrMod: HFHC\n               n miss p.miss mean  sd median p25 p75 min max  skew  kurt\nBenzoic_Acid0 13    0      0   19 2.8     19  17  21  13  22 -0.75 -0.26\n\np-values\n                pNormal pNonNormal\nBenzoic_Acid0 0.9158615  0.9652747\n\nStandardize mean differences\n               average    1 vs 2    1 vs 3     2 vs 3\nBenzoic_Acid0 0.120627 0.1662403 0.1023771 0.09326363\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\nOverall\nC\nHC\nHFHC\np\ntest\nSMD\n\n\n\n\nn\n34\n8\n13\n13\n\n\n\n\n\nBenzoic_Acid0 (median [IQR])\n19.14 [15.86, 21.58]\n18.60 [15.63, 22.04]\n20.22 [15.12, 21.62]\n19.03 [17.30, 21.43]\n0.965\nnonnorm\n0.121\n\n\n\n\n\n¬†\n\n\n\n\n\n\n\n\n\n\n\n(a) Benzoic_Acid at Month 0 : Baseline\n\n\n\n\n\n\n\n\n\n\n\n(b) Benzoic_Acid at Months 1-3 : Treatment\n\n\n\n\n\n\n\nFigure¬†19: Proportion of nutritional model instances per metabolite concentration quantile (denoted by the average value of concentrations within each quantile).\n\n\n\n¬†\n\n\n\n\n\n\n\n\n\n\n\n(a) Nutritional Model Odds Ratio on Benzoic_Acid. HC vs C difference\n\n\n\n\n\n\n\n\n\n\n\n\n\n(b) Nutritional Model Odds Ratio on Benzoic_Acid. HFHC vs C difference\n\n\n\n\n\n\n\n\n\n\n\n\n\n(c) Nutritional Model Odds Ratio on Benzoic_Acid. HFHC vs HC difference\n\n\n\n\n\n\n\nFigure¬†20: Average Treatment Effects (ATE)\n\n\n\n¬†\n\n\n\n\n\n\n\n\nFigure¬†21: Benzoic_Acid nutritional model differences from baseline at t0 (trends)\n\n\n\n\n\n¬†\n\n\n\n\n\n\n\n\nFigure¬†22: Benzoic_Acid nutritional model differences based on raw data. Dashed horizontal line corresponds to the adjustment value of Benzoic_Acid at time 0.\n\n\n\n\n\n¬†\n\n\n\n\n\n\n\n\nFigure¬†23: Benzoic_Acid nutritional model differences from baseline at t0 (split view). Points denote median concentrations and lines denote the corresponding central 80% likelihood intervals.\n\n\n\n\n\n¬†\n\n\n\n\n\n\n\n\n\n\n\n(a) Benzoic_Acid nutritional model differences versus Benzoic_Acid at time 0 (trends) using raw data.\n\n\n\n\n\n\n\n\n\n\n\n(b) Benzoic_Acid nutritional model differences versus Benzoic_Acid at time 0 (trends) using model adjustment.\n\n\n\n\n\n\n\nFigure¬†24: Effect of adjusting to baseline metabolite value at time 0. Without adjustment, graph (a), the differences of the nutritional models depend on the baseline value. With adjustment, graph (b), the differences of the nutritional models do not depend on the baseline value i.e.¬†trend lines are almost parallel to each other.",
    "crumbs": [
      "Sections",
      "Modeling"
    ]
  },
  {
    "objectID": "modeling_metabolic_syndrome.html#pyroglutamic---surrogate-of-uric-Œ±cid",
    "href": "modeling_metabolic_syndrome.html#pyroglutamic---surrogate-of-uric-Œ±cid",
    "title": "Modeling & Assessing Metabolic Syndrome In Rats (Metabolite Added Value)",
    "section": "Pyroglutamic - Surrogate Of Uric Œëcid",
    "text": "Pyroglutamic - Surrogate Of Uric Œëcid\nUric acid is a naturally occurring chemical compound in the body that serves as a vital marker for several metabolic and health conditions. It is the final waste product that results from the metabolic breakdown of purines.\n\nPurines are chemical substances that are components of DNA and RNA. They are found naturally in every cell in the human body, but they are also consumed through the diet, particularly in certain foods and drinks (like red meat, organ meats, seafood, and alcohol).\nThe body produces uric acid from these purines, mainly in the liver, and it typically dissolves in the blood.\nThe kidneys are responsible for filtering out most of the uric acid from the blood, which is then excreted from the body via urine.\n\nIn humans, uric acid also acts as a potent antioxidant in the blood, which can be a protective function.\nHigh Levels\nWhen the body either produces too much uric acid or the kidneys do not excrete enough of it, the level in the blood rises, a condition called hyperuricemia. This can lead to serious health issues:\n\nGout (Arthritis): This is the most well-known condition. When uric acid levels are too high, it can form sharp, needle-like monosodium urate crystals that deposit in the joints, triggering sudden, severe attacks of pain, swelling, and inflammation. The big toe is most commonly affected.\nKidney Stones: High concentrations of uric acid can crystallize in the kidneys, forming painful uric acid kidney stones.\nMetabolic & Cardiovascular Issues: Hyperuricemia is often associated with and may contribute to other conditions, including:\n\nHypertension (High blood pressure)\nChronic Kidney Disease (CKD)\nMetabolic Syndrome\nType 2 Diabetes\n\n\nNormal Range\nThe normal reference ranges for uric acid in the blood can vary slightly between laboratories and are generally different for men and women:\n\n\n\nGroup\nNormal Range (approx.)\n\n\n\n\nAdult Males\n\\(3.5 - 7.2 \\text{ mg/dL}\\)\n\n\nAdult Females\n\\(2.6 - 6.0 \\text{ mg/dL}\\)\n\n\n\nNote: The level that increases the risk of gout is often considered to be \\(\\text{&gt; 6.0 mg/dL}\\) or \\(\\text{&gt; 7.0 mg/dL}\\) as this is the point where the blood becomes saturated and crystals can begin to form.\nLow Uric Acid Levels\nWhile less common, lower-than-normal levels (hypouricemia) can also be a sign of underlying issues, such as:\n\nSevere liver disease.\nCertain rare inherited metabolic disorders.\nA side effect of some medications (e.g., those used to treat gout).\n\n\n\n[1] \"Uracil, Xanthine, Creatine, Serine, Isoleucine, Phenylalanine, Fructose, Glucose, Tyrosine, Adenosine, Methionine\"\n\n\n\n\n\n     ### Summary of continuous variables ###\n\nNutrMod: Overall\n               n miss p.miss mean   sd median p25  p75 min   max skew  kurt\nPyroglutamic0 34    0      0 4304 5937     25   1 9200   1 18183 0.94 -0.59\n------------------------------------------------------------------------------------------ \nNutrMod: C\n              n miss p.miss mean   sd median p25   p75 min   max skew kurt\nPyroglutamic0 8    0      0 5947 8277      1   1 14617   1 18183 0.71 -1.9\n------------------------------------------------------------------------------------------ \nNutrMod: HC\n               n miss p.miss mean   sd median p25  p75 min   max skew  kurt\nPyroglutamic0 13    0      0 3882 5408      1   1 8395   1 15480 0.98 -0.33\n------------------------------------------------------------------------------------------ \nNutrMod: HFHC\n               n miss p.miss mean   sd median p25  p75 min   max skew kurt\nPyroglutamic0 13    0      0 3716 5037    139   1 9235   1 11976 0.79 -1.4\n\np-values\n                pNormal pNonNormal\nPyroglutamic0 0.6816713  0.6613958\n\nStandardize mean differences\n                average    1 vs 2    1 vs 3     2 vs 3\nPyroglutamic0 0.2176336 0.2953509 0.3256828 0.03186713\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\nOverall\nC\nHC\nHFHC\np\ntest\nSMD\n\n\n\n\nn\n34\n8\n13\n13\n\n\n\n\n\nPyroglutamic0 (median [IQR])\n25.46 [1.00, 9,199.78]\n1.00 [1.00, 14,617.16]\n1.00 [1.00, 8,395.41]\n138.95 [1.00, 9,235.15]\n0.661\nnonnorm\n0.218\n\n\n\n\n\n¬†\n\n\n\n\n\n\n\n\n\n\n\n(a) Pyroglutamic at Month 0 : Baseline\n\n\n\n\n\n\n\n\n\n\n\n(b) Pyroglutamic at Months 1-3 : Treatment\n\n\n\n\n\n\n\nFigure¬†25: Proportion of nutritional model instances per metabolite concentration quantile (denoted by the average value of concentrations within each quantile).\n\n\n\n¬†\n\n\n\n\n\n\n\n\n\n\n\n(a) Nutritional Model Odds Ratio on Pyroglutamic. HC vs C difference\n\n\n\n\n\n\n\n\n\n\n\n\n\n(b) Nutritional Model Odds Ratio on Pyroglutamic. HFHC vs C difference\n\n\n\n\n\n\n\n\n\n\n\n\n\n(c) Nutritional Model Odds Ratio on Pyroglutamic. HFHC vs HC difference\n\n\n\n\n\n\n\nFigure¬†26: Average Treatment Effects (ATE)\n\n\n\n¬†\n\n\n\n\n\n\n\n\nFigure¬†27: Pyroglutamic nutritional model differences from baseline at t0 (trends)\n\n\n\n\n\n¬†\n\n\n\n\n\n\n\n\nFigure¬†28: Pyroglutamic nutritional model differences based on raw data. Dashed horizontal line corresponds to the adjustment value of Pyroglutamic at time 0.\n\n\n\n\n\n¬†\n\n\n\n\n\n\n\n\nFigure¬†29: Pyroglutamic nutritional model differences from baseline at t0 (split view). Points denote median concentrations and lines denote the corresponding central 80% likelihood intervals.\n\n\n\n\n\n¬†\n\n\n\n\n\n\n\n\n\n\n\n(a) Pyroglutamic nutritional model differences versus Pyroglutamic at time 0 (trends) using raw data.\n\n\n\n\n\n\n\n\n\n\n\n(b) Pyroglutamic nutritional model differences versus Pyroglutamic at time 0 (trends) using model adjustment.\n\n\n\n\n\n\n\nFigure¬†30: Effect of adjusting to baseline metabolite value at time 0. Without adjustment, graph (a), the differences of the nutritional models depend on the baseline value. With adjustment, graph (b), the differences of the nutritional models do not depend on the baseline value i.e.¬†trend lines are almost parallel to each other.\n\n\n\nPyroglutamic acid (also known as 5-oxoproline or pidolic acid) is a metabolic intermediate in the \\(\\gamma\\)-glutamyl cycle, which is the primary pathway the body uses to produce and recycle glutathione, its most powerful internal antioxidant.\nClinically, measuring pyroglutamic acid is important because it acts as a ‚Äúcanary in the coal mine‚Äù for glutathione depletion and certain metabolic disorders.\nThe \\(\\gamma\\)-Glutamyl Cycle\nPyroglutamic acid is produced in the liver, kidneys, and brain. In a healthy cycle, it is a temporary ‚Äústop‚Äù on the way to making glutamate. An enzyme called 5-oxoprolinase normally converts pyroglutamic acid into glutamate so the cycle can continue.\nIf this cycle is interrupted‚Äîeither because an enzyme is missing or because the body is under extreme stress‚Äîpyroglutamic acid ‚Äúleaks‚Äù out into the blood (pyroglutatmic acidemia) and urine (pyroglutamic aciduria).\nA doctor might measure pyroglutamic acid (usually via a urine organic acid test) to investigate a High Anion Gap Metabolic Acidosis (HAGMA)‚Äîa condition where the blood becomes too acidic for reasons that aren‚Äôt immediately obvious (like diabetes or kidney failure).\n\n1. Acquired Causes (Most Common)\n\nChronic Acetaminophen (Tylenol) Use: This is the most notorious cause. Acetaminophen depletes glutathione. When glutathione stores are low, the body‚Äôs feedback loop goes into overdrive to make more, accidentally causing an ‚Äúoverflow‚Äù of pyroglutamic acid.\nMalnutrition: A lack of the amino acids glycine or cysteine (the building blocks of glutathione) can cause the cycle to stall and pyroglutamic acid to build up.\nCertain Antibiotics: Drugs like flucloxacillin and vigabatrin can interfere with the enzymes in the cycle.\nSepsis or Liver Disease: Severe systemic illness can overwhelm the body‚Äôs antioxidant capacity.\n\n\n\n2. Genetic Causes (Rare)\n\nGlutathione Synthetase Deficiency: A rare inherited disorder that causes chronic high levels of pyroglutamic acid, leading to hemolytic anemia and neurological issues.\n5-Oxoprolinase Deficiency: A rare condition where the body cannot break down pyroglutamic acid, though this often has milder symptoms.\n\n\n\n\n\n\n\n\nLevel\nInterpretation\n\n\n\n\nNormal\nTypically \\(&lt; \\text{170 mmol/mol creatinine}\\) (Urine). A small amount is normal.\n\n\nElevated\nSuggests glutathione deficiency, oxidative stress, or specific drug interference.\n\n\nVery High\nOften indicates Pyroglutamic Acidosis, requiring medical intervention to balance blood pH.\n\n\n\nSymptoms of High Levels\nBecause elevated pyroglutamic acid often coincides with metabolic acidosis, symptoms may include: * Rapid breathing (tachypnea) or shortness of breath. * Confusion or mental ‚Äúfogginess.‚Äù * Extreme fatigue or malaise. * Nausea and vomiting.\nWhile pyroglutamic acid and uric acid are distinct molecules from two different metabolic pathways, they are ‚Äúbiochemical cousins‚Äù in the way they reflect the body‚Äôs antioxidant status and response to oxidative stress.\nThey are not directly made from one another, but they often ‚Äúreact‚Äù to the same health conditions.\n\n\n1. The Antioxidant Connection\nThe most significant link between them is their relationship to Glutathione, the body‚Äôs ‚Äúmaster antioxidant.‚Äù\n\nPyroglutamic Acid: High levels of this usually mean the glutathione levels are depleted. When we run out of glutathione, our cells are left unprotected against damage.\nUric Acid: Interestingly, uric acid is also a powerful antioxidant (it provides about \\(50\\%\\) of the antioxidant capacity in the blood).\nThe Link: When glutathione levels drop (marked by high pyroglutamic acid), the body sometimes increases uric acid production as a ‚Äúbackup‚Äù to help neutralize oxidative stress.\n\n\n\n2. Common Triggers\nYou will often see both markers move out of range due to the same underlying causes:\n\nKidney Function: Both are cleared from the body by the kidneys. If kidney function is sluggish, both pyroglutamic acid and uric acid can build up in the blood.\nAlcohol Consumption: Chronic alcohol use depletes glutathione (raising pyroglutamic acid) and simultaneously increases the breakdown of purines (raising uric acid).\nMetabolic Syndrome: Conditions like obesity and insulin resistance are high-stress states for the body. This stress can lead to lower glutathione stores and higher circulating uric acid.\n\n\n\n3. Key Differences at a Glance\n\n\n\n\n\n\n\n\nFeature\nPyroglutamic Acid\nUric Acid\n\n\n\n\nOrigin\nThe \\(\\gamma\\)-glutamyl cycle (Glutathione)\nPurine metabolism (DNA/RNA breakdown)\n\n\nPrimary Meaning\nShows Glutathione deficiency or ‚Äúwaste‚Äù\nShows Purine turnover or excretion issues\n\n\nMain Clinical Risk\nMetabolic Acidosis (blood becomes acidic)\nGout and Kidney Stones\n\n\nMajor Trigger\nAcetaminophen (Tylenol), Malnutrition\nHigh-purine diet, Alcohol, Dehydration\n\n\n\nIn short: They are not the same thing, but if a lab report shows both are high, it is a strong signal that the body is under significant oxidative stress or that the kidneys are having trouble processing metabolic waste.",
    "crumbs": [
      "Sections",
      "Modeling"
    ]
  },
  {
    "objectID": "modeling_metabolic_syndrome.html#arabitol",
    "href": "modeling_metabolic_syndrome.html#arabitol",
    "title": "Modeling & Assessing Metabolic Syndrome In Rats (Metabolite Added Value)",
    "section": "Arabitol",
    "text": "Arabitol\nContains 19 non-detected cases i.e.¬†1s, out of 101 total cases post baseline.",
    "crumbs": [
      "Sections",
      "Modeling"
    ]
  },
  {
    "objectID": "modeling_metabolic_syndrome.html#sorbitol",
    "href": "modeling_metabolic_syndrome.html#sorbitol",
    "title": "Modeling & Assessing Metabolic Syndrome In Rats (Metabolite Added Value)",
    "section": "Sorbitol",
    "text": "Sorbitol\nContains 39 non-detected cases i.e.¬†1s, out of 101 total cases post baseline.",
    "crumbs": [
      "Sections",
      "Modeling"
    ]
  },
  {
    "objectID": "modeling_metabolic_syndrome.html#theobromine",
    "href": "modeling_metabolic_syndrome.html#theobromine",
    "title": "Modeling & Assessing Metabolic Syndrome In Rats (Metabolite Added Value)",
    "section": "Theobromine",
    "text": "Theobromine\nContains 51 non-detected cases i.e.¬†1s, out of 101 total cases post baseline.",
    "crumbs": [
      "Sections",
      "Modeling"
    ]
  },
  {
    "objectID": "modeling_metabolic_syndrome.html#post-mortem-data",
    "href": "modeling_metabolic_syndrome.html#post-mortem-data",
    "title": "Modeling & Assessing Metabolic Syndrome In Rats (Metabolite Added Value)",
    "section": "Post-Mortem Data",
    "text": "Post-Mortem Data\n\n\n\n\n\n\n\n\n\n\n\n\nFigure¬†31: PCA of post-mortem clinical data. Variable and rat id biplot contributions. Variable contribution emphasis.\n\n\n\n\n\n\n\n\n\n\n\n\n\nFigure¬†32: PCA of post-mortem clinical data. Variable and rat id biplot contributions. Nutritional model separation emphasis.\n\n\n\n\n\n\n\n\n\n\n\n\n\n\nFigure¬†33: PCA of post-mortem clinical data. Explained variation distribution of the first 10 components.\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n(a) PCA of post-mortem clinical data. Contributions of variables to component 1.\n\n\n\n\n\n\n\n\n\n\n\n(b) PCA of post-mortem clinical data. Contributions of variables to component 2.\n\n\n\n\n\n\n\n\n\n\n\n(c) PCA of post-mortem clinical data. Contributions of variables to component 3\n\n\n\n\n\n\n\nFigure¬†34: A reference dashed line is also shown on the barplot. This reference line corresponds to the expected value if the contribution where uniform. For a given dimension, any variable with a contribution above the reference line could be considered as important in contributing to the dimension.\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\nFigure¬†35: PCA on post-mortem clinical data for viewing the separation among nutritional models. Focus on components 1 and 2.\n\n\n\n\n\n\n\n\n\n\n\n\n\nFigure¬†36: PCA on post-mortem clinical data for viewing the separation among nutritional models. Focus on components 1 and 4.\n\n\n\n\n\n\n\n\n\n\n\n\n\nFigure¬†37: PCA on post-mortem clinical data for viewing the separation among nutritional models. Focus on components 2 and 4.",
    "crumbs": [
      "Sections",
      "Modeling"
    ]
  },
  {
    "objectID": "modeling_metabolic_syndrome.html#longitudinal-data",
    "href": "modeling_metabolic_syndrome.html#longitudinal-data",
    "title": "Modeling & Assessing Metabolic Syndrome In Rats (Metabolite Added Value)",
    "section": "Longitudinal Data",
    "text": "Longitudinal Data\n\n\n\n\n\n\n\n\n\n\n\n\nFigure¬†38: PCA of metabolites‚Äô data. Variable and rat id biplot contributions. Variable contribution emphasis.\n\n\n\n\n\n\n\n\n\n\n\n\n\nFigure¬†39: PCA of metabolites‚Äô data. Variable and rat id biplot contributions. Time Point (Month) separation emphasis.\n\n\n\n\n\n\n\n\n\n\n\n\n\nFigure¬†40: PCA of metabolites‚Äô data. Variable and rat id biplot contributions. Nutritional Model separation emphasis.\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\nFigure¬†41: MFA of metabolites‚Äô data. Biplot of individuals and qualitative variables.\n\n\n\n\n\n\n\n\n\n\n\n\n\n\nFigure¬†42: MFA of metabolites‚Äô data. Explained variation distribution of the first 10 components.\n\n\n\n\n\n\n\n\n\n\n\n\nPer Time or Month - Unadjusted for Time 0\n\n\n\n\n\n\n\n\n\n\n\n\nFigure¬†43: PCA of metabolites‚Äô data. Biplot of individuals and variables at time 0.\n\n\n\n\n\n\n\n\n\n\n\n\n\nFigure¬†44: PCA of metabolites‚Äô data. Biplot of individuals and variables at time 1.\n\n\n\n\n\n\n\n\n\n\n\n\n\nFigure¬†45: PCA of metabolites‚Äô data. Biplot of individuals and variables at time 2.\n\n\n\n\n\n\n\n\n\n\n\n\n\nFigure¬†46: PCA of metabolites‚Äô data. Biplot of individuals and variables at time 3.\n\n\n\n\n\n\n\n\nPer Time or Month - Adjusted for Time 0\n\n\n\n\n\n\n\n\n\n\n\n\nFigure¬†47: PCA of metabolites‚Äô data. Biplot of individuals and variables at time 0. Adjusted for the median value of each metabolite at time 0.\n\n\n\n\n\n\n\n\n\n\n\n\n\nFigure¬†48: PCA of metabolites‚Äô data. Biplot of individuals and variables at time 1. Adjusted for the median value of each metabolite at time 0.\n\n\n\n\n\n\n\n\n\n\n\n\n\nFigure¬†49: PCA of metabolites‚Äô data. Biplot of individuals and variables at time 2. Adjusted for the median value of each metabolite at time 0.\n\n\n\n\n\n\n\n\n\n\n\n\n\nFigure¬†50: PCA of metabolites‚Äô data. Biplot of individuals and variables at time 3. Adjusted for the median value of each metabolite at time 0.",
    "crumbs": [
      "Sections",
      "Modeling"
    ]
  },
  {
    "objectID": "modeling_metabolic_syndrome.html#p-hba",
    "href": "modeling_metabolic_syndrome.html#p-hba",
    "title": "Modeling & Assessing Metabolic Syndrome In Rats (Metabolite Added Value)",
    "section": "P-HBA",
    "text": "P-HBA\n\n\n\n\n\n\n\n\n\n\n\n(a) p_hba at Month 0 : Baseline\n\n\n\n\n\n\n\n\n\n\n\n(b) p_hba at Months 1-3 : Treatment\n\n\n\n\n\n\n\nFigure¬†135: Proportion of nutritional model instances per metabolite concentration quantile (denoted by the average value of concentrations within each quantile).\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n(a) Nutritional Model Odds Ratio on p_hba. HC vs C difference\n\n\n\n\n\n\n\n\n\n\n\n\n\n(b) Nutritional Model Odds Ratio on p_hba. HFHC vs C difference\n\n\n\n\n\n\n\n\n\n\n\n\n\n(c) Nutritional Model Odds Ratio on p_hba. HFHC vs HC difference\n\n\n\n\n\n\n\nFigure¬†136: Average Treatment Effects (ATE)\n\n\n\n\n\n\n\n\n\n\n\nFigure¬†137: p_hba nutritional model differences from baseline at t0 (trends)\n\n\n\n\n\n\n\n\n\n\n\n\n\nFigure¬†138: p_hba nutritional model differences based on raw data. Dashed horizontal line corresponds to the adjustment value of p_hba at time 0.\n\n\n\n\n\n\n\n\n\n\n\n\n\nFigure¬†139: p_hba nutritional model differences from baseline at t0 (split view). Points denote median concentrations and lines denote the corresponding central 80% likelihood intervals.\n\n\n\n\n\n¬†\n\nChanges Through Treatment Time\n¬†\n\n\n\n\n\n\n\n\n\n\n\n(a) Month 1\n\n\n\n\n\n\n\n\n\n\n\n(b) Month 2\n\n\n\n\n\n\n\n\n\n\n\n(c) Month 3\n\n\n\n\n\n\n\nFigure¬†140: Median difference of p_hba fold concentration changes from baseline. Vertical 95% confidence intervals are for the median (top plot) and the median difference (bottom plot) in each graph.",
    "crumbs": [
      "Sections",
      "Modeling"
    ]
  },
  {
    "objectID": "modeling_metabolic_syndrome.html#dopamine",
    "href": "modeling_metabolic_syndrome.html#dopamine",
    "title": "Modeling & Assessing Metabolic Syndrome In Rats (Metabolite Added Value)",
    "section": "Dopamine",
    "text": "Dopamine\n\n\n\n\n\n\n\n\n\n\n\n(a) dopamine at Month 0 : Baseline\n\n\n\n\n\n\n\n\n\n\n\n(b) dopamine at Months 1-3 : Treatment\n\n\n\n\n\n\n\nFigure¬†141: Proportion of nutritional model instances per metabolite concentration quantile (denoted by the average value of concentrations within each quantile).\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n(a) Nutritional Model Odds Ratio on dopamine. HC vs C difference\n\n\n\n\n\n\n\n\n\n\n\n\n\n(b) Nutritional Model Odds Ratio on dopamine. HFHC vs C difference\n\n\n\n\n\n\n\n\n\n\n\n\n\n(c) Nutritional Model Odds Ratio on dopamine. HFHC vs HC difference\n\n\n\n\n\n\n\nFigure¬†142: Average Treatment Effects (ATE)\n\n\n\n\n\n\n\n\n\n\n\nFigure¬†143: dopamine nutritional model differences from baseline at t0 (trends)\n\n\n\n\n\n\n\n\n\n\n\n\n\nFigure¬†144: dopamine nutritional model differences based on raw data. Dashed horizontal line corresponds to the adjustment value of dopamine at time 0.\n\n\n\n\n\n\n\n\n\n\n\n\n\nFigure¬†145: dopamine nutritional model differences from baseline at t0 (split view). Points denote median concentrations and lines denote the corresponding central 80% likelihood intervals.\n\n\n\n\n\n¬†\n\nChanges Through Treatment Time\n¬†\n\n\n\n\n\n\n\n\n\n\n\n(a) Month 1\n\n\n\n\n\n\n\n\n\n\n\n(b) Month 2\n\n\n\n\n\n\n\n\n\n\n\n(c) Month 3\n\n\n\n\n\n\n\nFigure¬†146: Median difference of dopamine fold concentration changes from baseline. Vertical 95% confidence intervals are for the median (top plot) and the median difference (bottom plot) in each graph.",
    "crumbs": [
      "Sections",
      "Modeling"
    ]
  },
  {
    "objectID": "modeling_metabolic_syndrome.html#kynurenine",
    "href": "modeling_metabolic_syndrome.html#kynurenine",
    "title": "Modeling & Assessing Metabolic Syndrome In Rats (Metabolite Added Value)",
    "section": "Kynurenine",
    "text": "Kynurenine\n\n\n\n\n\n\n\n\n\n\n\n(a) kynurenine at Month 0 : Baseline\n\n\n\n\n\n\n\n\n\n\n\n(b) kynurenine at Months 1-3 : Treatment\n\n\n\n\n\n\n\nFigure¬†147: Proportion of nutritional model instances per metabolite concentration quantile (denoted by the average value of concentrations within each quantile).\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n(a) Nutritional Model Odds Ratio on kynurenine. HC vs C difference\n\n\n\n\n\n\n\n\n\n\n\n\n\n(b) Nutritional Model Odds Ratio on kynurenine. HFHC vs C difference\n\n\n\n\n\n\n\n\n\n\n\n\n\n(c) Nutritional Model Odds Ratio on kynurenine. HFHC vs HC difference\n\n\n\n\n\n\n\nFigure¬†148: Average Treatment Effects (ATE)\n\n\n\n\n\n\n\n\n\n\n\nFigure¬†149: kynurenine nutritional model differences from baseline at t0 (trends)\n\n\n\n\n\n\n\n\n\n\n\n\n\nFigure¬†150: kynurenine nutritional model differences based on raw data. Dashed horizontal line corresponds to the adjustment value of kynurenine at time 0.\n\n\n\n\n\n\n\n\n\n\n\n\n\nFigure¬†151: kynurenine nutritional model differences from baseline at t0 (split view). Points denote median concentrations and lines denote the corresponding central 80% likelihood intervals.\n\n\n\n\n\n¬†\n\nChanges Through Treatment Time\n¬†\n\n\n\n\n\n\n\n\n\n\n\n(a) Month 1\n\n\n\n\n\n\n\n\n\n\n\n(b) Month 2\n\n\n\n\n\n\n\n\n\n\n\n(c) Month 3\n\n\n\n\n\n\n\nFigure¬†152: Median difference of kynurenine fold concentration changes from baseline. Vertical 95% confidence intervals are for the median (top plot) and the median difference (bottom plot) in each graph.",
    "crumbs": [
      "Sections",
      "Modeling"
    ]
  },
  {
    "objectID": "modeling_metabolic_syndrome.html#clustered-image-maps-1",
    "href": "modeling_metabolic_syndrome.html#clustered-image-maps-1",
    "title": "Modeling & Assessing Metabolic Syndrome In Rats (Metabolite Added Value)",
    "section": "Clustered Image Maps",
    "text": "Clustered Image Maps\nUsing the amino acids as per the comparison table in the beginning of this section i.e.¬†amino acids that have shown significant difference in either the C to HC direction or the C to HFHC direction.\n\nControl (C) To High Carbs (HC)\n¬†\n\n\n\n\n\n\n\n\n\n\n\n(a) Month 1\n\n\n\n\n\n\n\n\n\n\n\n(b) Month 2\n\n\n\n\n\n\n\n\n\n\n\n(c) Month 3\n\n\n\n\n\n\n\nFigure¬†164: PCA on each treatment month and using the log fold change of amino acid concentration from baseline. Blue color denotes the Control group while orange color denotes the High Carbs nutritional model.\n\n\n\n¬†\n\n\n\n\n\n\n\n\nFigure¬†165: Clustered heatmap of amino acid concentration fold changes of month 1 from baseline. Here the significant lipids are used that have been found to have a large difference between the Controlsand High Carbs nutritional models. The vertical purple dotted line on the left cuts the amino acid dendrogram into 4 clusters.\n\n\n\n\n\n¬†\n\n\n\n\n\n\n\n\nFigure¬†166: Clustered heatmap of amino acid concentration fold changes of month 2 from baseline. Here the significant lipids are used that have been found to have a large difference between the Controlsand High Carbs nutritional models. The vertical purple dotted line on the left cuts the amino acid dendrogram into 3 clusters.\n\n\n\n\n\n¬†\n\n\n\n\n\n\n\n\nFigure¬†167: Clustered heatmap of amino acid concentration fold changes of month 3 from baseline. Here the significant lipids are used that have been found to have a large difference between the Controlsand High Carbs nutritional models. The vertical purple dotted line on the left cuts the amino acid dendrogram into 5 clusters.\n\n\n\n\n\n¬†\n\n\nControl (C) To High Fat High Carbs (HC)\n¬†\n\n\n\n\n\n\n\n\n\n\n\n(a) Month 1\n\n\n\n\n\n\n\n\n\n\n\n(b) Month 2\n\n\n\n\n\n\n\n\n\n\n\n(c) Month 3\n\n\n\n\n\n\n\nFigure¬†168: PCA on each treatment month and using the log fold change of amino acid concentration from baseline. Blue color denotes the Control group while orange color denotes the High Fat High Carbs nutritional model.\n\n\n\n¬†\n\n\n\n\n\n\n\n\nFigure¬†169: Clustered heatmap of amino acid concentration fold changes of month 1 from baseline. Here the significant lipids are used that have been found to have a large difference between the Controlsand High Fat High Carbs nutritional models. The vertical purple dotted line on the left cuts the amino acid dendrogram into 5 clusters.\n\n\n\n\n\n¬†\n\n\n\n\n\n\n\n\nFigure¬†170: Clustered heatmap of amino acid concentration fold changes of month 2 from baseline. Here the significant lipids are used that have been found to have a large difference between the Controlsand High Fat High Carbs nutritional models. The vertical purple dotted line on the left cuts the amino acid dendrogram into 4 clusters.\n\n\n\n\n\n¬†\n\n\n\n\n\n\n\n\nFigure¬†171: Clustered heatmap of amino acid concentration fold changes of month 3 from baseline. Here the significant lipids are used that have been found to have a large difference between the Controlsand High Fat High Carbs nutritional models. The vertical purple dotted line on the left cuts the amino acid dendrogram into 4 clusters.",
    "crumbs": [
      "Sections",
      "Modeling"
    ]
  },
  {
    "objectID": "modeling_metabolic_syndrome.html#melatonin",
    "href": "modeling_metabolic_syndrome.html#melatonin",
    "title": "Modeling & Assessing Metabolic Syndrome In Rats (Metabolite Added Value)",
    "section": "Melatonin",
    "text": "Melatonin\n\n\n\n\n\n\n\n\n\n\n\n(a) melatonin at Month 0 : Baseline\n\n\n\n\n\n\n\n\n\n\n\n(b) melatonin at Months 1-3 : Treatment\n\n\n\n\n\n\n\nFigure¬†178: Proportion of nutritional model instances per metabolite concentration quantile (denoted by the average value of concentrations within each quantile).\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n(a) Nutritional Model Odds Ratio on melatonin. HC vs C difference\n\n\n\n\n\n\n\n\n\n\n\n\n\n(b) Nutritional Model Odds Ratio on melatonin. HFHC vs C difference\n\n\n\n\n\n\n\n\n\n\n\n\n\n(c) Nutritional Model Odds Ratio on melatonin. HFHC vs HC difference\n\n\n\n\n\n\n\nFigure¬†179: Average Treatment Effects (ATE)\n\n\n\n\n\n\n\n\n\n\n\nFigure¬†180: melatonin nutritional model differences from baseline at t0 (trends)\n\n\n\n\n\n\n\n\n\n\n\n\n\nFigure¬†181: melatonin nutritional model differences based on raw data. Dashed horizontal line corresponds to the adjustment value of melatonin at time 0.\n\n\n\n\n\n\n\n\n\n\n\n\n\nFigure¬†182: melatonin nutritional model differences from baseline at t0 (split view). Points denote median concentrations and lines denote the corresponding central 80% likelihood intervals.\n\n\n\n\n\n¬†\n\nChanges Through Treatment Time\n¬†\n\n\n\n\n\n\n\n\n\n\n\n(a) Month 1\n\n\n\n\n\n\n\n\n\n\n\n(b) Month 2\n\n\n\n\n\n\n\n\n\n\n\n(c) Month 3\n\n\n\n\n\n\n\nFigure¬†183: Median difference of melatonin fold concentration changes from baseline. Vertical 95% confidence intervals are for the median (top plot) and the median difference (bottom plot) in each graph.",
    "crumbs": [
      "Sections",
      "Modeling"
    ]
  },
  {
    "objectID": "modeling_metabolic_syndrome.html#indole-3-acetic-acid",
    "href": "modeling_metabolic_syndrome.html#indole-3-acetic-acid",
    "title": "Modeling & Assessing Metabolic Syndrome In Rats (Metabolite Added Value)",
    "section": "Indole-3-Acetic Acid",
    "text": "Indole-3-Acetic Acid\n\n\n\n\n\n\n\n\n\n\n\n(a) indole3acetic_acid at Month 0 : Baseline\n\n\n\n\n\n\n\n\n\n\n\n(b) indole3acetic_acid at Months 1-3 : Treatment\n\n\n\n\n\n\n\nFigure¬†179: Proportion of nutritional model instances per metabolite concentration quantile (denoted by the average value of concentrations within each quantile).\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n(a) Nutritional Model Odds Ratio on indole3acetic_acid. HC vs C difference\n\n\n\n\n\n\n\n\n\n\n\n\n\n(b) Nutritional Model Odds Ratio on indole3acetic_acid. HFHC vs C difference\n\n\n\n\n\n\n\n\n\n\n\n\n\n(c) Nutritional Model Odds Ratio on indole3acetic_acid. HFHC vs HC difference\n\n\n\n\n\n\n\nFigure¬†180: Average Treatment Effects (ATE)\n\n\n\n\n\n\n\n\n\n\n\nFigure¬†181: indole3acetic_acid nutritional model differences from baseline at t0 (trends)\n\n\n\n\n\n\n\n\n\n\n\n\n\nFigure¬†182: indole3acetic_acid nutritional model differences based on raw data. Dashed horizontal line corresponds to the adjustment value of indole3acetic_acid at time 0.\n\n\n\n\n\n\n\n\n\n\n\n\n\nFigure¬†183: indole3acetic_acid nutritional model differences from baseline at t0 (split view). Points denote median concentrations and lines denote the corresponding central 80% likelihood intervals.\n\n\n\n\n\n¬†\n\nChanges Through Treatment Time\n¬†\n\n\n\n\n\n\n\n\n\n\n\n(a) Month 1\n\n\n\n\n\n\n\n\n\n\n\n(b) Month 2\n\n\n\n\n\n\n\n\n\n\n\n(c) Month 3\n\n\n\n\n\n\n\nFigure¬†184: Median difference of indole3acetic_acid fold concentration changes from baseline. Vertical 95% confidence intervals are for the median (top plot) and the median difference (bottom plot) in each graph.",
    "crumbs": [
      "Sections",
      "Modeling"
    ]
  },
  {
    "objectID": "modeling_metabolic_syndrome.html#serotonin",
    "href": "modeling_metabolic_syndrome.html#serotonin",
    "title": "Modeling & Assessing Metabolic Syndrome In Rats (Metabolite Added Value)",
    "section": "Serotonin",
    "text": "Serotonin\n\n\n\n\n\n\n\n\n\n\n\n(a) serotonin at Month 0 : Baseline\n\n\n\n\n\n\n\n\n\n\n\n(b) serotonin at Months 1-3 : Treatment\n\n\n\n\n\n\n\nFigure¬†184: Proportion of nutritional model instances per metabolite concentration quantile (denoted by the average value of concentrations within each quantile).\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n(a) Nutritional Model Odds Ratio on serotonin. HC vs C difference\n\n\n\n\n\n\n\n\n\n\n\n\n\n(b) Nutritional Model Odds Ratio on serotonin. HFHC vs C difference\n\n\n\n\n\n\n\n\n\n\n\n\n\n(c) Nutritional Model Odds Ratio on serotonin. HFHC vs HC difference\n\n\n\n\n\n\n\nFigure¬†185: Average Treatment Effects (ATE)\n\n\n\n\n\n\n\n\n\n\n\nFigure¬†186: serotonin nutritional model differences from baseline at t0 (trends)\n\n\n\n\n\n\n\n\n\n\n\n\n\nFigure¬†187: serotonin nutritional model differences based on raw data. Dashed horizontal line corresponds to the adjustment value of serotonin at time 0.\n\n\n\n\n\n\n\n\n\n\n\n\n\nFigure¬†188: serotonin nutritional model differences from baseline at t0 (split view). Points denote median concentrations and lines denote the corresponding central 80% likelihood intervals.\n\n\n\n\n\n¬†\n\nChanges Through Treatment Time\n¬†\n\n\n\n\n\n\n\n\n\n\n\n(a) Month 1\n\n\n\n\n\n\n\n\n\n\n\n(b) Month 2\n\n\n\n\n\n\n\n\n\n\n\n(c) Month 3\n\n\n\n\n\n\n\nFigure¬†189: Median difference of serotonin fold concentration changes from baseline. Vertical 95% confidence intervals are for the median (top plot) and the median difference (bottom plot) in each graph.",
    "crumbs": [
      "Sections",
      "Modeling"
    ]
  },
  {
    "objectID": "modeling_metabolic_syndrome.html#p-coumaric-acid-sulfate-1",
    "href": "modeling_metabolic_syndrome.html#p-coumaric-acid-sulfate-1",
    "title": "Modeling & Assessing Metabolic Syndrome In Rats (Metabolite Added Value)",
    "section": "P-Coumaric Acid Sulfate",
    "text": "P-Coumaric Acid Sulfate\n\n\n\n\n\n\n\n\n\n\n\n(a) p_coumaric_acid_sulfate at Month 0 : Baseline\n\n\n\n\n\n\n\n\n\n\n\n(b) p_coumaric_acid_sulfate at Months 1-3 : Treatment\n\n\n\n\n\n\n\nFigure¬†191: Proportion of nutritional model instances per metabolite concentration quantile (denoted by the average value of concentrations within each quantile).\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n(a) Nutritional Model Odds Ratio on p_coumaric_acid_sulfate. HC vs C difference\n\n\n\n\n\n\n\n\n\n\n\n\n\n(b) Nutritional Model Odds Ratio on p_coumaric_acid_sulfate. HFHC vs C difference\n\n\n\n\n\n\n\n\n\n\n\n\n\n(c) Nutritional Model Odds Ratio on p_coumaric_acid_sulfate. HFHC vs HC difference\n\n\n\n\n\n\n\nFigure¬†192: Average Treatment Effects (ATE)\n\n\n\n\n\n\n\n\n\n\n\nFigure¬†193: p_coumaric_acid_sulfate nutritional model differences from baseline at t0 (trends)\n\n\n\n\n\n\n\n\n\n\n\n\n\nFigure¬†194: p_coumaric_acid_sulfate nutritional model differences based on raw data. Dashed horizontal line corresponds to the adjustment value of p_coumaric_acid_sulfate at time 0.\n\n\n\n\n\n\n\n\n\n\n\n\n\nFigure¬†195: p_coumaric_acid_sulfate nutritional model differences from baseline at t0 (split view). Points denote median concentrations and lines denote the corresponding central 80% likelihood intervals.\n\n\n\n\n\n¬†\n\nChanges Through Treatment Time\n¬†\n\n\n\n\n\n\n\n\n\n\n\n(a) Month 1\n\n\n\n\n\n\n\n\n\n\n\n(b) Month 2\n\n\n\n\n\n\n\n\n\n\n\n(c) Month 3\n\n\n\n\n\n\n\nFigure¬†196: Median difference of p_coumaric_acid_sulfate fold concentration changes from baseline. Vertical 95% confidence intervals are for the median (top plot) and the median difference (bottom plot) in each graph.",
    "crumbs": [
      "Sections",
      "Modeling"
    ]
  },
  {
    "objectID": "modeling_metabolic_syndrome.html#clustered-image-maps-2",
    "href": "modeling_metabolic_syndrome.html#clustered-image-maps-2",
    "title": "Modeling & Assessing Metabolic Syndrome In Rats (Metabolite Added Value)",
    "section": "Clustered Image Maps",
    "text": "Clustered Image Maps\nWe use the amino acids as per the comparison table in the beginning of this section i.e.¬†amino acids that have shown significant difference in either the C to HC direction or the C to HFHC direction.\n\nControl (C) To High Carbs (HC)\n\n\n\n\n\n\n\n\n\n\n\n(a) Month 1\n\n\n\n\n\n\n\n\n\n\n\n(b) Month 2\n\n\n\n\n\n\n\n\n\n\n\n(c) Month 3\n\n\n\n\n\n\n\nFigure¬†196: PCA on each treatment month and using the log fold change of amino acid concentration from baseline. Blue color denotes the Control group while orange color denotes the High Carbs nutritional model.\n\n\n\n¬†\n\n\n\n\n\n\n\n\nFigure¬†197: Clustered heatmap of amino acid concentration fold changes of month 1 from baseline. Here the significant lipids are used that have been found to have a large difference between the Controlsand High Carbs nutritional models. The vertical purple dotted line on the left cuts the amino acid dendrogram into 2 clusters.\n\n\n\n\n\n¬†\n\n\n\n\n\n\n\n\nFigure¬†198: Clustered heatmap of amino acid concentration fold changes of month 2 from baseline. Here the significant lipids are used that have been found to have a large difference between the Controlsand High Carbs nutritional models. The vertical purple dotted line on the left cuts the amino acid dendrogram into 3 clusters.\n\n\n\n\n\n¬†\n\n\n\n\n\n\n\n\nFigure¬†199: Clustered heatmap of amino acid concentration fold changes of month 3 from baseline. Here the significant lipids are used that have been found to have a large difference between the Controlsand High Carbs nutritional models. The vertical purple dotted line on the left cuts the amino acid dendrogram into 2 clusters.\n\n\n\n\n\n¬†\n\n\nControl (C) To High Fat High Carbs (HC)\n\n\n\n\n\n\n\n\n\n\n\n(a) Month 1\n\n\n\n\n\n\n\n\n\n\n\n(b) Month 2\n\n\n\n\n\n\n\n\n\n\n\n(c) Month 3\n\n\n\n\n\n\n\nFigure¬†200: PCA on each treatment month and using the log fold change of amino acid concentration from baseline. Blue color denotes the Control group while orange color denotes the High Fat High Carbs nutritional model.\n\n\n\n¬†\n\n\n\n\n\n\n\n\nFigure¬†201: Clustered heatmap of amino acid concentration fold changes of month 1 from baseline. Here the significant lipids are used that have been found to have a large difference between the Controlsand High Fat High Carbs nutritional models. The vertical purple dotted line on the left cuts the amino acid dendrogram into 3 clusters.\n\n\n\n\n\n¬†\n\n\n\n\n\n\n\n\nFigure¬†202: Clustered heatmap of amino acid concentration fold changes of month 2 from baseline. Here the significant lipids are used that have been found to have a large difference between the Controlsand High Fat High Carbs nutritional models. The vertical purple dotted line on the left cuts the amino acid dendrogram into 3 clusters.\n\n\n\n\n\n¬†\n\n\n\n\n\n\n\n\nFigure¬†203: Clustered heatmap of amino acid concentration fold changes of month 3 from baseline. Here the significant lipids are used that have been found to have a large difference between the Controlsand High Fat High Carbs nutritional models. The vertical purple dotted line on the left cuts the amino acid dendrogram into 3 clusters.",
    "crumbs": [
      "Sections",
      "Modeling"
    ]
  },
  {
    "objectID": "notes_metabolic_syndrome.html",
    "href": "notes_metabolic_syndrome.html",
    "title": "notes_metabolic_syndrome",
    "section": "",
    "text": "References & Research Notes\n\nhttps://stats.stackexchange.com/questions/637773/why-does-harrell-argue-for-ignoring-y-during-data-reduction\n\nOne of the worst things you can do with data is to take a huge number of collinear features and predict to find the ‚Äúright‚Äù features that predict Y.\n\nhttps://stats.stackexchange.com/questions/296164/does-it-make-sense-to-run-a-stepwise-regression-on-components-estimated-through\nhttps://stats.stackexchange.com/questions/441860/isnt-it-futile-to-try-to-fix-multicollinearity\n\nIf the goal is prediction then your proposed solution sounds agreeable, but inference is a whole other beast.\nThe fact is that the theory, for example concerning sampling distributions of coefficients, is not capable of conditioning in such model selection procedures. Frank Harrell talks a little bit about this in Regression Modelling Strategies in the section about stepwise regression.\nStatistics is not an algorithmic truth generating process. You need to be able to say ‚ÄúI think X is related to the outcome‚Äù in order to make inferences of the nature statistics affords us.\n\nhttps://stats.stackexchange.com/questions/515412/circular-reasoning-in-harrell-bbr-18-19\n\nyou agree and understand why we should prefer c-index and likelihood ratio chi square (LHRCS) to classification accuracy\n\nhttps://stats.stackexchange.com/questions/621395/how-can-i-automatically-perform-multiple-linear-regressions-in-r-to-identify-the\n\nMy advice is to NOT automate this. There are a variety of methods to do automated model selection (forward, backward, stepwise). Of these, the only ones that I would use are penalized methods such as LASSO. What you seem to want is all subsets regression, which is possible in R. There are a few methods (you can Google ‚Äúall subsets regression in R‚Äù to find some) but these aren‚Äôt good. P values will be too low, standard errors too small, models too complex and parameter estimates biased away from 0. (See Frank Harrell‚Äôs book Regression Modeling Strategies for details, examples, proofs and so on).\nWorse: It stops you from thinking.\nChoose models that make sense. Just a few of them. Compare those. You‚Äôve already shown us that you‚Äôve done some of this.\nIf you are interested in uncovering interactions, then trees (or some offshoot of them) may be good. I‚Äôm not sure why you are opposed.\nIf you want to look at combinations of variables, and don‚Äôt need to include the original variables, then partial least squares might be good. From the variables you‚Äôve listed, it looks like the first component will be ‚Äúsize‚Äù, but that may be fine.\nHarrell: The worst thing I can think of saying about variable selection methods is that they fail at what they pretend to do. They can‚Äôt select the right variables. And small changes in the dataset result in different variables selected. They there is their destruction of standard errors ‚Ä¶\n\nhttps://stats.stackexchange.com/questions/201061/whats-wrong-with-data-guided-modeling-in-regression\nhttps://stats.stackexchange.com/questions/200242/minimum-number-of-observations-needed-for-penalized-regression/200368#200368\n\nPenalized estimation can be used for very small sample sizes; it‚Äôs just that the estimates will be shrunk to the mean very heavily, so the estimates will be conservative. But the intercept in the model is not shrunk\n\nhttps://stats.stackexchange.com/questions/491861/penalized-or-standard-logistic-regression"
  },
  {
    "objectID": "modeling_metabolic_syndrome.html#phenol-sulfate",
    "href": "modeling_metabolic_syndrome.html#phenol-sulfate",
    "title": "Modeling & Assessing Metabolic Syndrome In Rats (Metabolite Added Value)",
    "section": "Phenol Sulfate",
    "text": "Phenol Sulfate\n\n\n\n\n\n\n\n\n\n\n\n(a) phenol_sulfate at Month 0 : Baseline\n\n\n\n\n\n\n\n\n\n\n\n(b) phenol_sulfate at Months 1-3 : Treatment\n\n\n\n\n\n\n\nFigure¬†153: Proportion of nutritional model instances per metabolite concentration quantile (denoted by the average value of concentrations within each quantile).\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n(a) Nutritional Model Odds Ratio on phenol_sulfate. HC vs C difference\n\n\n\n\n\n\n\n\n\n\n\n\n\n(b) Nutritional Model Odds Ratio on phenol_sulfate. HFHC vs C difference\n\n\n\n\n\n\n\n\n\n\n\n\n\n(c) Nutritional Model Odds Ratio on phenol_sulfate. HFHC vs HC difference\n\n\n\n\n\n\n\nFigure¬†154: Average Treatment Effects (ATE)\n\n\n\n\n\n\n\n\n\n\n\nFigure¬†155: phenol_sulfate nutritional model differences from baseline at t0 (trends)\n\n\n\n\n\n\n\n\n\n\n\n\n\nFigure¬†156: phenol_sulfate nutritional model differences based on raw data. Dashed horizontal line corresponds to the adjustment value of phenol_sulfate at time 0.\n\n\n\n\n\n\n\n\n\n\n\n\n\nFigure¬†157: phenol_sulfate nutritional model differences from baseline at t0 (split view). Points denote median concentrations and lines denote the corresponding central 80% likelihood intervals.\n\n\n\n\n\n¬†\n\nChanges Through Treatment Time\n¬†\n\n\n\n\n\n\n\n\n\n\n\n(a) Month 1\n\n\n\n\n\n\n\n\n\n\n\n(b) Month 2\n\n\n\n\n\n\n\n\n\n\n\n(c) Month 3\n\n\n\n\n\n\n\nFigure¬†158: Median difference of phenol_sulfate fold concentration changes from baseline. Vertical 95% confidence intervals are for the median (top plot) and the median difference (bottom plot) in each graph.",
    "crumbs": [
      "Sections",
      "Modeling"
    ]
  },
  {
    "objectID": "modeling_metabolic_syndrome.html#dopamine-1",
    "href": "modeling_metabolic_syndrome.html#dopamine-1",
    "title": "Modeling & Assessing Metabolic Syndrome In Rats (Metabolite Added Value)",
    "section": "Dopamine",
    "text": "Dopamine\n\n\n\n\n\n\n\n\n\n\n\n(a) dopamine at Month 0 : Baseline\n\n\n\n\n\n\n\n\n\n\n\n(b) dopamine at Months 1-3 : Treatment\n\n\n\n\n\n\n\nFigure¬†190: Proportion of nutritional model instances per metabolite concentration quantile (denoted by the average value of concentrations within each quantile).\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n(a) Nutritional Model Odds Ratio on dopamine. HC vs C difference\n\n\n\n\n\n\n\n\n\n\n\n\n\n(b) Nutritional Model Odds Ratio on dopamine. HFHC vs C difference\n\n\n\n\n\n\n\n\n\n\n\n\n\n(c) Nutritional Model Odds Ratio on dopamine. HFHC vs HC difference\n\n\n\n\n\n\n\nFigure¬†191: Average Treatment Effects (ATE)\n\n\n\n\n\n\n\n\n\n\n\nFigure¬†192: dopamine nutritional model differences from baseline at t0 (trends)\n\n\n\n\n\n\n\n\n\n\n\n\n\nFigure¬†193: dopamine nutritional model differences based on raw data. Dashed horizontal line corresponds to the adjustment value of dopamine at time 0.\n\n\n\n\n\n\n\n\n\n\n\n\n\nFigure¬†194: dopamine nutritional model differences from baseline at t0 (split view). Points denote median concentrations and lines denote the corresponding central 80% likelihood intervals.\n\n\n\n\n\n¬†\n\nChanges Through Treatment Time\n¬†\n\n\n\n\n\n\n\n\n\n\n\n(a) Month 1\n\n\n\n\n\n\n\n\n\n\n\n(b) Month 2\n\n\n\n\n\n\n\n\n\n\n\n(c) Month 3\n\n\n\n\n\n\n\nFigure¬†195: Median difference of dopamine fold concentration changes from baseline. Vertical 95% confidence intervals are for the median (top plot) and the median difference (bottom plot) in each graph.",
    "crumbs": [
      "Sections",
      "Modeling"
    ]
  },
  {
    "objectID": "modeling_metabolic_syndrome.html#tryptophan-to-kynurenine-ratio-adhoc",
    "href": "modeling_metabolic_syndrome.html#tryptophan-to-kynurenine-ratio-adhoc",
    "title": "Modeling & Assessing Metabolic Syndrome In Rats (Metabolite Added Value)",
    "section": "Tryptophan To Kynurenine Ratio (adhoc)",
    "text": "Tryptophan To Kynurenine Ratio (adhoc)",
    "crumbs": [
      "Sections",
      "Modeling"
    ]
  },
  {
    "objectID": "modeling_metabolic_syndrome.html#tryptophan-to-kynurenic-acid-ratio-adhoc",
    "href": "modeling_metabolic_syndrome.html#tryptophan-to-kynurenic-acid-ratio-adhoc",
    "title": "Modeling & Assessing Metabolic Syndrome In Rats (Metabolite Added Value)",
    "section": "Tryptophan To Kynurenic Acid Ratio (adhoc)",
    "text": "Tryptophan To Kynurenic Acid Ratio (adhoc)\n\n\n\n\n\n\n\n\n\n\n\n(a) tkAcid_ratio at Month 0 : Baseline\n\n\n\n\n\n\n\n\n\n\n\n(b) tkAcid_ratio at Months 1-3 : Treatment\n\n\n\n\n\n\n\nFigure¬†159: Proportion of nutritional model instances per metabolite concentration quantile (denoted by the average value of concentrations within each quantile).\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n(a) Nutritional Model Odds Ratio on tkAcid_ratio. HC vs C difference\n\n\n\n\n\n\n\n\n\n\n\n\n\n(b) Nutritional Model Odds Ratio on tkAcid_ratio. HFHC vs C difference\n\n\n\n\n\n\n\n\n\n\n\n\n\n(c) Nutritional Model Odds Ratio on tkAcid_ratio. HFHC vs HC difference\n\n\n\n\n\n\n\nFigure¬†160: Average Treatment Effects (ATE)\n\n\n\n\n\n\n\n\n\n\n\nFigure¬†161: tkAcid_ratio nutritional model differences from baseline at t0 (trends)\n\n\n\n\n\n\n\n\n\n\n\n\n\nFigure¬†162: tkAcid_ratio nutritional model differences based on raw data. Dashed horizontal line corresponds to the adjustment value of tkAcid_ratio at time 0.\n\n\n\n\n\n\n\n\n\n\n\n\n\nFigure¬†163: tkAcid_ratio nutritional model differences from baseline at t0 (split view). Points denote median concentrations and lines denote the corresponding central 80% likelihood intervals.",
    "crumbs": [
      "Sections",
      "Modeling"
    ]
  }
]